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BACTERIAL AND FUNGAL PROFILE OF ACUTE 
EXACERBATION OF CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE  
ABSTRACT 
BACKGROUND AND OBJECTIVE: Acute exacerbation of Chronic obstructive 
Pulmonary disease (AECOPD) is defined as a sustained worsening of the patient’s condition 
,from the stable state in the patient’s baseline dyspnoea and cough or sputum ,or both and 
beyond normal day to day variation ,that is acute in  onset and necessitates a change in 
regular medication in a patient with underlying COPD as per Gold guidelines ..It leads to 
significant increase in morbidity and mortality in COPD patients. Bacteria are responsible for 
60% of exacerbation. The aim of our study was to determine the bacterial and fungal isolates 
in   AECOPD and Stable COPD patients with special reference to antibiotic susceptibility and 
their resistance pattern from hospital data. 
 
SETTINGS AND DESIGN : It was a Cross sectional study carried out at the Institute of 
Microbiology, Madras Medical  College in association with Departments of Internal 
Medicine, Thoracic Medicine, Intensive Medicare Care Unit at Rajiv Gandhi Government 
General Hospital, Chennai from October 2013 to September 2014 
 
 MATERIALS AND METHODS : The Study population consisted of  150 in patients 
presenting with signs and symptom of AECOPD and   50 stable COPD  out  patients .All the  
respiratory samples were subjected to direct gram staining , culture ,biochemical  reactions 
and the isolates  were identified ac-cording to standard techniques. Antibiotic sensitivity was 
done by Kirby-Bauer method according to CLSI standards. 
  
RESULTS  : COPD was common in age group of sixty to seventy one. Both AECOPD and 
Stable COPD patients had male predominance .Tobacco smoking was  strongly associated 
with study group.  Respiratory failure  8% was the most common complication .Positive 
bacteriological culture was obtained in 70.6% of cases. Mixed infection among AECOPD 
patients was found in 3.8% of culture positive cases. Sputum purulence was significantly 
correlated with the culture positivity . The commonest organism in the respiratory samples in 
AECOPD patients were Gram negative  bacteria 74.5% as compared to Gram positive 
bacteria 21.6.Among Gram negative organisms Klebsiella pneumoniae 33.3% was the most 
commonly and significantly isolated organism  followed by Pseudomonas aeruginosa .In 
stable COPD patients only 19% Klebsiella pneumoniae was isolated. Non fermenters  were 
significantly isolated in Severe type and Staphylococcus aureus from Moderate type. 
Klebsiella pneumoniae   showed Multi drug resistance(MDR)  of 29.7%  The prevalence of 
Carbapenemase production in  Klebsiella pneumoniae   was 28.5%This implies that 
Klebsiella pneumoniae was one of the important drug resistant  pathogen isolated  among  
AECOPD patients. Presence of MRSA and ESBL isolates were higher in Moderate AECOPD  
patients (66.6%, 66.6% , respectively) than in severe group(33.3%,33.3%). Penicillin  
resistant  Streptococcus  pneumoniae  , Imipenem resistance, Carbapenamase  producing 
isolates,Amp C producing strain were significantly higher in severe AECOPD patients MDR 
pathogens were present both in moderate and severe type of COPD. 
Haemophilus influenzae and Fungus were not isolated. 
 
CONCLUSION : The bacterial etiology of AECOPD is different in India from what has 
been shown in western studies..To conclude Gram negative bacteria were more frequently 
isolated in our patients, antimicrobial treatment should be started early depending on the 
antimicrobial sensitivity results, in the wake of an increasing rate of isolation of resistant 
organisms. 
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BACTERIAL AND FUNGAL PROFILE OF ACUTE 
EXACERBATION OF CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE 
 
INTRODUCTION 
 
 Chronic Obstructive Pulmonary Disease (COPD ) is defined as a preventable 
and treatable disease with pulmonary component  characterised by airflow limitation 
that is of not  fully reversible which  is usually progressive and associated with an 
abnormal inflammatory response  of the lungs to noxious particles or gases and  some 
significant  extrapulmonary effects that may contribute to the severity in individual 
patients (1-3). It includes: Emphysema, Chronic Bronchitis, Small airway disease 
 
 AECOPD(acute exacerbation of COPD): This condition is defined as a 
sustained worsening of the patient’s condition ,from the stable state(in the patient’s 
baseline dyspnoea and cough or sputum ,or both and beyond normal day to day 
variation ,that is acute in  onset and necessitates a change in regular medication in a 
patient with underlying COPD as per Gold guidelines (4). It is characterized  by 
presence of increased sputum volume, sputum purulence and dyspnoea. 
 
 Burden of the disease : Chronic obstructive pulmonary disease (COPD) is 
associated with significant morbidity and mortality, with the World Health 
Organization estimating its rise from being the fourth to the third leading cause of 
death by 2030. The mortality rates are supposed to increase by 30% every decade(5). 
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Almost 95%  of mortality due to chronic respiratory disease in India can be assigned 
to COPD.  
 
 Exacerbations of COPD have considerable impact on health care system at 
both primary and tertiary care levels as they are the major reason for antibiotic use and 
admissions. WHO has estimated that 600 million people worldwide have COPD. 
Additionally, exacerbations lead to indirect costs because of days lost from work. 
COPD affects 30% of patients seen in chest clinics and constitutes 1-25% of hospital 
admissions all over India(6). 
 
 AE-COPD is a common cause of emergency room (ER) visits and is a major 
cause of morbidity and mortality (7.8). 
 
 A gross underestimate of COPD Prevalence had been estimated as 17 million 
and it is likely to increase by over 30% in next decade. Highest prevalence (9.4%) was 
reported from North Indian rural population from a study conducted by Jindal et.el 
from 1964-1995. 
 
Causes of AE-COPD:   
 Exacerbations are caused or triggered by a variety of factors including viruses, 
bacteria ,and air pollutants, and are associated with acutely increased worsening of 
existing (acute-on-chronic) airway inflammation and also due to defects in host 
defence mechanisms. Alterations produced in the bronchial epithelium by the 
damaging action of smoking favour bacterial adhesion and colonization. In turn, 
airway colonization and chronic infection contribute to progressive pulmonary 
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damage via the action of proinflammatory substances in what is known as the “vicious 
circle theory(9).  
 
 Infections are the important cause of acute exacerbation. Bacteria are 
responsible for   causing   60% of    exacerbations. Viral infections are the likely cause 
of approximately 30% of exacerbations, while PCR studies have suggested that up to 
40% of acute respiratory infections in COPD are associated with viruses. Fungal 
isolates have not been reported(3,10). 
 
 Exacerbations, mostly of an infectious etiology, are a frequent cause of 
morbidity in COPD patients. Furthermore, infection was the most common observable 
cause of death in prospectively followed-up COPD patients(11). 
 
 This condition is highly serious in our country as the prevalence of smoking   
and air pollution is very high which are the main cause for COPD and increase the 
frequency of exacerbation. Little has been documented about this problem from India. 
 
 Exacerbations punctuate the clinical course of COPD in many patients. Since it 
is a vicious cycle recurrent exacerbation will lead to rapid deterioration of lung 
parameters and early death due to respiratory failure and increased economic burden. 
These episodes of acute exacerbation can vary considerably in severity as part of the 
exacerbations will remain unreported while some episodes require admission. A 
European survey found that sputum analysis of exacerbated patients is requested only   
in 10% of cases (11). 
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 Antimicrobial therapy: Over 90% of patients with AECOPD are treated   with 
antibiotics, on empirical basis   without proper sputum analysis  so the effectiveness of 
treatment is uncertain due to emerging new strains and their resistant pattern thereby 
leading to recurrent exacerbation(113). It would be useful to find the proper etiology of 
COPD exacerbations, thereby facilitating the orientation of antibiotic treatment and 
reducing the high number of failures recorded with empiric treatment, which in some 
cases, is as high as 26%(114). 
 
 This study is taken up to find out the Bacteriological & Fungal profile and their 
sensitivity pattern in AECOPD and Stable COPD patients as the knowledge of 
possible bacterial & fungal etiology and sensitivity patterns of COPD exacerbations, 
facilitates the orientation of antibacterial and antifungal treatment   so that timely 
institution of correct management is important for better prognosis of disease and to 
improve the quality of life of the patient. 
 
  
  
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 
HISTORICAL REVIEW: 
 The  term exacerbation  has its origin in the Latin descriptive acerbus, meaning 
harsh, bitter, sharp and more at outer edge. 
 
 Hippocrates (460-377BC):  The Father of Medicine described an old men 
suffering from breathlessness associated with cough and catarrhal 
 
Earliest references to COPD  
 In  1679  Bonet described Chronic Obstructive Pulmonary Disease (COPD) as 
“voluminous lungs”. It was corroborated around a century later in 1769 by  Morgagni 
who described cases in which the lungs  were “turgid”, particularly  from air. 
 
 Baillie in 1789  published a series of illustrations of the emphysematous lung 
putting forth the  pathology of the disease. Thus emphysema was known to be a part 
of COPD. 
 
 It was much later that chronic bronchitis got included in COPD.  
 
 Badham in 1814 used the word catarrh to refer to the chronic cough and 
increased mucus secretion  as symptoms of bronchiolitis  and chronic bronchitis that 
could be part of COPD. 
 
 Laënnec described emphysema of the lungs in 1821 in his Treatise of diseases 
of  the chest. He was the inventor of the stethoscope who wrote that emphysema lungs 
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were excessively inflated that did not empty well. Laënnec went on to describe a 
combination of  emphysema and chronic bronchitis. Our present knowledge of the 
disease is founded on the clinical work of Laennec. 
 
 In 1855 Bierner was given the credit for  studying the sputum in  
Bronchopulmonary disease.             
 
 In 1846 John Hutchinson invented the spirometer. This was the key to  
diagnosing COPD. The spirometer is still used today for diagnosis and regular 
assessment regarding  response to therapy in COPD. Hutchinson’s instrument only 
measured vital capacity.  
 
 In 1915 Dass and Luetscher  studied and described the application of 
bacteriological sputum examination and recognised  Haemophilus influenza as a 
common cause of acute and chronic Bronchitis 
 
 In 1947   Tiffeneau and Pinelli added the concept of timed vital capacity as a 
measure of airflow. 
 
 In 1964 Eriksson showed that people with a severe congenital deficiency of 
serum α1 antitrypsin developed Emphysema. 
 
 William Briscoe is believed to be first person to use the term COPD in 
discussion at the 9th   Aspen Emphysema conference. This term became established 
and today we refer to COPD as the designation of this growing health problem.(9,12)  
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DEFINITION : 
 Chronic Obstructive Pulmonary Disease (COPD ) is defined as a preventable 
and treatable disease with pulmonary component  characterised by airflow limitation 
that is of not  fully reversible which  is usually progressive and associated with an 
abnormal inflammatory response  of the lungs to noxious particles or gases and  some 
significant  extrapulmonary effects that may contribute to the severity in individual 
patients. (1,2) 
 
 It was also defined in a joint statement of American Thoracic Society and the 
European Respiratory Society as a disease characterised by and diagnosed with 
spirometric measurement of airflow limitation that is not fully reversible which is also 
supported by GOLD.(13) 
 
COPD includes Emphysema, Chronic Bronchitis, Small airway disease. 
 
 Emphysema : It is defined as an abnormal ,permanent enlargement of the distal 
airspaces ,distal to the terminal bronchioles ,accompanied by destruction of their walls 
and without obvious fibrosis. 
 
 Chronic Bronchitis:  A clinically defined condition with presence of chronic 
productive cough on most days for 3 months in each of 2 consecutive years in a 
patient in whom other causes of chronic cough have been excluded.(3)    
 
 Small airway disease : It is a condition in which small bronchioles are 
narrowed . 
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DISEASE CLASSIFICATION: 
 COPD is a heterogenous disease  which has many  hypotheses like British, 
American, Dutch, Swedish and all the hypotheses probably have elements of truth as 
COPD is a classic gene –by-environment disease. 
 
 In newer literature COPD severity is classified as per   2006 revision of  GOLD 
criteria that is based on post bronchodilator lung function 
 
GOLD 1(mild) FEV1/FVC <0.70 and FEV1 >= 80% predicted 
GOLD 2 (moderate) FEV1/FVC <0.70 and 80% > FEV1 >= 50% predicted 
GOLD3(severe) FEV1/FVC <0.70 and50% > FEV1 >= 30% predicted 
GOLD 4(very severe) 
FEV1/FVC <0.70 and FEV1 <30% predicted or FEV1 < 
50% predicted plus chronic respiratory failure or signs 
of heart failure 
 
 People with FEV1/FVC >=0.70 and respiratory symptoms of chronic cough and 
sputum production are no longer included as COPD stage (formely GOLD stage 
0).Patients with  FEV1/FVC >=0.70 but an FVC <80% predicted meet spirometric 
criteria for a restrictive process. Although this is not regarded as COPD ,patients 
might present with several symptoms similar to those seen in COPD ,and these 
patients have an increased risk of death.(14) 
 
 AECOPD(acute exacerbation of COPD): This condition is defined as a 
sustained worsening of the patient’s condition ,from the stable state(in the patient’s 
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baseline dyspnoea and cough or sputum ,or both and beyond normal day to day 
variation ,that is acute in  onset and necessitates a change in regular medication in a 
patient with underlying COPD as per Gold guidelines (4) 
 
Anthosien criteria :(15) 
 Increased breathlessness 
 Increased volume of sputum 
 Increased purulence of sputum 
 
 There are 3 types of acute exacerbations of chronic bronchitis which are based 
upon 3 cardinal symptoms which include worsening of dyspnea, increase in sputum 
purulence, and increase in sputum volume. The 3 types are defined as follows:  
 
1. Type 3: Mild exacerbation with 1 of 3 cardinal symptoms PLUS 1 of the following:  
a. Upper respiratory tract infection in the past 5 days  
b. Fever without other apparent cause  
c. Increased wheezing  
d. Increased cough  
e. Increased respiratory rate or heart rate by 20% above baseline  
 
2. Type 2: Moderate exacerbation with 2 of 3 cardinal symptoms 
 
3. Type 1: Severe exacerbation with all 3 cardinal symptoms 
 Cardinal symptoms include worsening of dyspnea, increase in sputum 
purulence, and increase in sputum volume .(16) 
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BURDEN OF DISEASE :  
 COPD is a growing global epidemic and it is estimated to kill around 3 million 
people every year .It is currently the 4th  largest killer disease in the world and 
expected to climb to 3rd position by the year 2030  . 
 
 WHO has estimated that 600 million people worldwide have COPD. It  affects  
around  5-10% of population over the age of 40 years but still there wide variations in 
the prevalence between countries.(17) 
 
ECONOMIC BURDEN:  
 The National Heart , lung and Blood Institute provides a estimate of 38.8 
billion US $ for US and 38.6 billion US $ for Europe .COPD accounts for 56% of 
total health care budget. 
 
 According to National Commission on macroeconomics and health published 
in India that per capital expenditure on COPD is Rs.42664 in 2006 and expected to 
increase to Rs. 62630  by 2016. Upto 84% of the costs spent on COPD is due to 
inpatient hospitalization due to which the loss in productivity due to COPD account 
for between 40% and 67% of the overall costs across the world .Hence it is a severe 
economic burden for countries throughout the world.(10) 
 
 Morbidity: In Canada 1 in 4 people older than 35 years was likely to be 
diagnosed with COPD. The burden was more in rural men ,with lower socioeconomic 
status (Eurorespiratory society annual congress in Amsterdam ,Netherlands 2011). 
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 In Canada by about 80 years about 25% of women and about 30% of men will 
be diagnosed with COPD.(18) 
 
 8-22% of adults aged more than 40 years and older is the leading cause of 
hospitalization and health care cost incurrence (19.)It is a common and leading cause of 
morbidity which is the major cause of worsening of Quality of life.50% of patients 
who survive first hospitalization  get readmitted within 6 months . Estimated 
prevalence rates for people more than 30 years vary between 0.6% and 4% in men and 
0.2 – 32%  in women(yin an et al.Passive smoking exposure and risk of COPD among 
adults in China .(20) 
 
INDIA:  
 A gross underestimate of COPD Prevalence had been estimated as 17 million 
and it is likely to increase by over 30% in next decade. Highest prevalence(9.4%) was 
reported from North Indian rural population from a study conducted by Jindal et.el 
from 1964-1995(10) . 
 
MORTALITY: 
 Global mortality: WHO states that more than 3 million people die of COPD per 
year and 5% of all deaths globally and 160%  in South east asian region over the next 
two decades. India itself contributes to over half of a million deaths second only to 
China .These mortality rates are supposed to increase by 30% every decade(5)   
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SOUTH EAST ASIAN REGION :(5) 
 Almost 5,56,000 deaths are attributable to COPD as estimated by WHO in 
South east asian region which majorily comprises INDIA .So almost 95%  of 
mortality due to chronic respiratory disease in India can be assigned to COPD. State 
wise data is at present available for Maharashtra .As the data for other states are not 
available  , studies on COPD is a must to assess the burden. 
 
DALYS (Disability adjusted life year):  
 In 1990 COPD accounted for 2.1% of DALY’S which ranked 12th most 
common cause .This is expected to increase upto  4.1%  and it is assumed to move to 
5th  rank by 2020.(20,21).Overall COPD was estimated to have resulted in more than  26 
million DALYS in 2000. 
 
 In the year 2002 6740 thousand DALYs were lost due to COPD in South East 
Asian region. 
 
 In India COPD account for 3% of DALYS but this is likely to be 
underestimated .(17) 
 
DEFENCE MECHANISM OF NORMAL LUNG RESIDENT DEFENSES 
 1. Airway architecture 
 2. Epithelial barrier 
 3. Mucociliary clearance 
 4. Soluble factors in airway secretion –complement,immunoglobulins 
 5. Alveolar macrophages 
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Recruited Defenses 
 If resident defence system is not able to control the Polymorphonuclear  
neutrophils and lymphocytes are recruited to augment host response by the production 
of Leukotriene β 4,TNF- α.(22) 
 
RISK FACTORS FOR COPD(106,107): 
1. Smoking-cigarrete or Bidi-50% of smokers develop COPD.73% of mortality in 
COPD is due to smoking among which 40% is from low and middle 
socioeconomic status. Smoking leads to ciliary destruction and hypermucus 
secretion and decreased mucociliary clearance. 
2. Aging-As the lung function starts to decline by third and fourth decade of life 
3. Tuberculosis (this is very common in India) 
4. Respiratory infection in early life 
5. Passive or second hand smoking 
6. Ambient air pollution-WHO estimates 1% of COPD cases in high income 
countries is due to urban air pollution where as it is 2% in nations of low and 
middle income. 
7. Occupational exposure-coal mining,cotton textile dust, mining 
8. House hold exposure-biomass fuels -Ninety percent of rural households and 
32% of urban households cook their meals on a biomass stove.3 billion people 
are exposed to biomass all over the world and it carries the   same amount of 
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risk of developing   COPD as tobacco smoke. WHO states that 35%  of  
population in countries of low and middle income develop COPD due to its 
inhalation  and 36% of mortality  from lower respiratory  disease is due 
biomass inhalation. 
9. Low Socioeconomic status 
10. Genetic factors-α1 antitrypsin deficiency leads to emphysema in 1-3% of 
patients 
11. Gender-In high income countries COPD prevalence is similar in both sexes due 
to smoking where as condition is different in low and middle income countries  
as smoking in female  is low .(23) 
 
PATHOLOGICAL CHANGE IN COPD: 
                                          Triggers – Cigarrette smoke, Biomass fuel 
                                                             
            Subepithelial infiltration                                                        Inflammatory 
                                                                                                           mediators                      
           Macrophages                                                                        Growth factors  
           Neutrophils                                                                           Proteinases ,                                  
           Oxidative stress 
           CD 8 
           CD 47                                                                         
 
                                 Emphysema                                          Chronic Bronchitis                                   
                         Air trapping dyspnoea                              Cough and hypermucus  
                                                                                                     Secretion 
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PATHOPHYSIOLOGY OF AECOPD:(3.10) 
1. In COPD patients  due to defective phagocytosis  of macrophages  it  leads to 
constant bacterial colonization of respiratory tract   and frequent  ,recurrent  
exacerbation of COPD. This can amplify and lead to increase airway and 
systemic   inflammation in Stable COPD patients  and this vicious cycle 
increases progressively with disease severity. As airflow obstruction progresses 
the frequency of exacerbation also increases.(24,25)As an increase in 
concentration of bacteria that colonize the lower respiratory tract  constitutes to 
the pathogenesis of exacerbation  and the  acquisition of new bacterial strain 
are also crucial in the pathogenesis of  exacerbation.(26) 
 
2. Alveolar macrophages from COPD patients   phagocytose  lesser number of 
apoptotic epithelial cells  .Therefore there is chronic  bacterial colonization 
with   Streptococcus pneumonia ,Haemophilus influenzae   which attributes to  
acute infectious exacerbation .(27) 
 
EFFECT OF COPD EXACERBATION WITH  FREQUENT 
EXACERBATION:(Vicious cycle) 
                                                                                                                           
 
 
                                                                        
  
          
HIGHER MORTALITY POOR QUALITY OF LIFE 
PATIENTS WITH FREQUENT EXACERBATION
FASTER DECLINE IN LUNG 
FUNCTION 
GREATER AIRWAY 
INFLAMMATION 
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CAUSES   OF ACUTE EXACERBATION OF COPD:(3,28) 
 
INFECTIOUS AGENTS : 
 Virus , Gram positive and gram negative aerobic bacterial, atypical bacteria 
 
ENVIRONMENTAL CONDITIONS:  
 Sudden change in temperature ,humidity,air pollution exposure,tobacco smoke 
exposure,noxious gases or irritating chemicals 
 
HOST FACTORS:  
 Patients with poor general health, poor nutrition, immunocompromised state 
,lack of compliance to prescribed medicines,adoption of unhealthy life styles modes, 
poor level of personal hygiene,lack of compliance with long term oxygen therapy, 
failure to participate in pulmonary rehabilitation. 
 
FACTORS THAT POTENTIALLY MODIFY RISK FACTORS OF AECOPD\ 
INTRINSIC FACTORS 
 Impairement of lung functions 
 Active smoking 
 Bronchial hyperresponsiveness 
 Chronic Mucus secretion 
 Impairement of defence mechanism 
 Non specific factors: increase age, comorbid illness 
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EXTRINSIC FACTORS: 
 Type of bacterial infection  and changing strains of bacteria 
 Decreased environmental temperature 
 Air pollution 
 Type of treatment for Stable and exacerbation of COPD 
 
TRIGGERS OF COPD EXACERBATIONS AND ASSOCIATED 
PATHOPHYSIOLOGICAL CHANGES LEADING TO INCREASED 
EXACERBATION SYMPTOMS 
                    Bacteria                             viruses                                  Pollutants 
 
 
                            Effects                Inflammed  COPD airway 
 
 
                                                  Greater airway inflammation 
 
               Systemic inflammation                                     Bronchoconstriction , edema 
 
                                                                                                         Expiratory flow limitation 
                                                                                                 
 
        Cardiovascular comorbidity         Exacerbation  Dynamic hyperinflation  
                                                                     Symptoms  
 
 Among all causes infection is the most common precipitating factor .Molecular 
diagnostics have given strong evidence that Microorganisms are involved in 80% of 
cases but the interaction between microorganisms and host is more important .(3,9,10) 
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Viral infections:  
 It accounts for 30% of infection but it could be an underestimate as it is 
difficult to isolate. The common viruse are Rhinovirus, Coronavirus, Influenza virus, 
Parainfluenza virus, Adenovirus, Respiratory syncytial virus 
 
Bacterial infections:  
 It accounts for 60% of infection. Most common are Haemophilus influenzae  
nontypable, Moraxella  Catarrhalis, Streptococcus pneumoniae.A number of studies 
have shown that virulent organisms are isolated in severe AECOPD patients like 
Staphylococcus aureus, Pseudomonas aeruginosa and members of Enterobactericeae 
family.(10) 
 
Atypical bacteria:  
 The role of Chlamydia , Legionella and Mycoplasma is conflicting in causing 
AECOPD as these microorganisms might also interact with airway bacteria and 
viruses. A study done by using real time PCR  by Diederen .et.al. found no role for 
these atypical bacteria in AECOPD.(29) 
 
 Potter et.al. proved that although a variety of commensal bacteria inhabits 
nasopharynx of all healthy individuals but still lower airways are usually found to be 
sterile by standard culture techniques(30). 
 
In Stable COPD: 
 The precise role of bacteria in causing exacerbation has been difficult to assess 
as lower airway in  stable COPD patients are colonised by same organisms as those 
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isolated at exacerbations like Haemophilus influenzae nontypable, Moraxella  
Catarrhalis, Streptococcus pneumoniae , Pseudomonas aeruginosa and also consists 
of other oropharyngeal commensal bacteria like-Streptococcus viridans, 
Streptococci,Neisseria sp,Corynebacterium sp,and Candida sp. A study by Wilkinson 
TM Donald son et.al.found that bacteria was isolated in 48.2% of stable COPD  
patients  which rose to 70% in AECOPD patients.(31)A study by Berenson .et. al. 
isolated bacteria in 25% of stable COPD and 50% in AECOPD(32). 
 
 Purulent sputum is the surrogate marker of bacterial infection since isolation 
rate of bacteria is more in purulent sputum as compared to mucoid sputum. 
 
 Since in this study we have correlated every sample with proper history, 
predominant growth , sputum  quality ,gram staining  so this can solve the dispute. 
 
Clinical features: (10) 
 Clinical features  include increase in cough, chest pain, Increase in 
breathlessness, Increase in sputum volume and change in it’s colour(white, green, 
yellow or blood streaked), Fever ,Increased  fatigue ,Increase in oxygen requirement. 
 
 Physical findings-tachycardia, tachypnoea, expirtory wheeze, medium to coarse 
crackles, pursed lip breathing, central and peripheral cyanosis, neck vein distention, 
hepatomegaly, peripheral edema, hyperinflation of lungs with increased AP diameter 
of thorax and depressed diaphragm. 
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COMPLICATION: 
 Hypoxemic Type 1 respiratory failure 
 Hypercapnic Type 3 respiratory failure 
 Compensated Metabolic alkalosis 
 Cor pulmonale  
 Left ventricular failure 
 Multi organ failure 
 Arterial oxygen desaturation 
 Altered sensorium 
 As per the National clinical guideline for the treatment of COPD (33). 
 
LABORATORY DIAGNOSIS: 
 Proper diagnosis of AECOPD depends on clinical history, Physical 
examination and associated with Microbiological investigations. Microbiological 
investigations are important to isolate the organisms and to determine it’s resistance 
pattern in order to prescribe the appropriate drug and to reduce the development new 
resistant strains and to prevent spread of existing resistant strains. 
 
OTHER INVESTIGATIONS: 
 Pulmonary Function test, Complete blood count , Chest radiography, Complete 
metabolic profile, Arterial Blood gas analysis, Oxygen saturation, ECG, 
Echocardiography if required. 
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Microbiological investigations : (34,35,36,106,109) 
 The major benefit of microbiological investigations lies in the proper 
etiological diagnosis of AECOPD and to identify the resistance and susceptibility 
pattern of microorganisms. Different   samples are collected  from lower respiratory 
tract to perform different microbiological investigations. The   most samples are: 
 
A. Non invasive: 
1. Sputum (Expectorated): Collected under direct supervision, to minimise 
contamination with oropharyngeal secretions.It is the easy and basic sample to 
assess the lower respiratory tract. 
 
2. Induced sputum: Collected in patients who are unable to produce sputum. 
Those are the material directly obtained from alveolar spaces and should be 
accepted in laboratory without prescreening. 
 
B. Invasive (Bronchoscopic techniques): 
1. Bronchial washings  
2. Bronchoalveolar lavage(BAL) 
3. Protected catheter bronchial brush(rare sample) 
 
Other Samples: 
 Endotracheal aspirate: 
 
D. Blood : 
 As a routine investigations 
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A. Microscopy: 
 Direct microscopy examination  aids to determine the quality of sample ,and to 
determine the severity and type of inflammatory response. To screen the likely 
pathogens directly in the clinical specimen and to   correlate with the organisms grown 
in culture .With this initial screening ,the laboratory can help the clinicians to make 
early decisions to initiate antibiotic therapy early. 
 
1. Staining methods :(34,35,36)  Direct  staining  provides a differential  staining and 
they enhance the chance of identifying the microbes and other details in the sample. 
 
i) Gram’s stain:  it is meant for evaluating the quality of the specimen , 
presence of bacteria and it’s arrangement, morphology, gram reactions , 
presence of neutrophils and also help  to identify fungal elements . 
 
ii) Acid Fast stain:  Helps  to identify acid fast bacilli  directly in clinical 
samples 
 
2. 10% Potassium hydroxide mount: It is used  to identify fungal elements in the 
specimen. 
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SCREENING OF SPECIMENS REQUESTED FOR ROUTINE BACTERIAL 
CULTURE TO ENSURE QUALITY (37,106,109) 
SPECIMEN 
SCREENING 
METHOD 
ACCEPTABLE 
FOR CULTURE 
NO FURTHER 
TESTING; request 
another sample 
Sputum  
Microscopic 
examination of gram 
stained smear 
<10 squamous 
epithelial 
cells/average 
10xfield 
>10 squamous 
epithelial 
cells/average 
10xfield 
Endotracheal  
Aspirate 
Microscopic 
examination of gram 
stained smear 
<10 squamous 
epithelial 
cells/average 
10xfield and 
bacteria seen in 
atleast 1 of 20 oil 
immersion fields 
>10 squamous 
epithelial 
cells/average 
10xfield and no 
bacteria seen in 
atleast 1 of 20 oil 
immersion fields 
Bronchoalveolar 
lavage or 
Bronchial wash 
Microscopic 
examination of gram 
stained smear 
<1%  of cells 
present are 
squamous epithelial 
cells 
>1% of cells present 
are squamous 
epithelial cells 
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REQUIREMENTS FOR CULTURE AND CONDITIONS:(34,35,38) 
Media 
Incubation 
Culture 
reading 
Pathogens that 
grow 
Time Temperature Atmosphere 
5%sheep 
Blood agar 
Upto 
48  
 
hrs  
 
37 degree C 5-10% Co2 Daily   
Streptococcus 
species, 
Staph.aureus, 
Moraxella 
Catarrhalis 
Chocolate 
agar 
Upto 
48 hrs 37 degree C 5-10% Co2 
Daily  
 
Streptococcus 
spp. 
5% Horse 
chocolate 
agar 
Upto 
48-72 
hrs 
37 degree C 5-10%CO2 with humidity Daily  
Haemophilus 
spp 
MacConkey 
agar 
Upto 
48 hrs 37 degree C Ambient air 
Daily  
 
Enterobacteriac
eae, 
Non fermentors 
Tryptic  Soy 
broth 
Upto 
72 hrs 37 degree C Ambient air Daily  
Blood culture 
broth 
Sabouraud 
Dextrose 
Agar with 
antibiotics 
Upto 4 
weeks 
 
25°C and 
37°C 
 
Ambient air 
 
Daily for 
1 week, 
twice 
weekly 
for 
next 
3weeks 
weeks 
Fungi 
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C) Antigen detection :  
 Counter current immunoelectrophoresis can be used to detect Streptococcus 
pneumoniae antigen in sputum. (56) 
 
D) Serology: (40,41,42) 
 Indirect immunofluorescent assay for the simultaneous diagnosis in human 
serum of IgM antibodies of the main infectious agents of the respiratory tract is  used 
for detection of atypical pathogens.Serologic assays for the detection of Specific Ig M 
antibody ,has been found to be very useful in detecting AECOPD caused by atypical 
pathogens and viruses ,which are difficult to grow by culture methods. It can be 
determined by ELISA. Biological markers   like determination of Interleukines  
tumour necrosis factor α (TNFα), interleukin‐1β (IL‐1β), and the chemoattractants 
leukotriene B4 (LTB4), interleukin 8 (CXCL8), and growth‐related oncogene α 
(GROα), Procalcitonin,C-reactive protein by ELISA .  
 
E) Polymerase Chain Reaction : 
 PCR is an important technique which gives confirmatory result and higher 
diagnostic yield along with conventional diagnostic methods.PCR is useful for 
available for Streptococcus pneumoniae, Haemophilus influenzae, Moraxella 
catarrhalis, and for many respiratory viruses 
 
ANTIMICROBIAL THERAPY:(3,10) 
 Antibiotic prevention of exacerbations is a highly researched topic in COPD. 
Both the GOLD guidelines and European Respiratory society/European society of 
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Clinical Microbiology and Infectious disease(ESCMID) guidelines for lower 
respiratory tract infections management suggest that antibiotics should be given to 
AECOPD patients according to Anthosien criteria with1)all 3 cardinal 
symptoms.2)with either of two symptoms in which increased sputum purulence is one 
among. 3) mechanically ventilated patients .4)patients with severe COPD. The 
recommended duration for antibiotics is 3-7 days. Patients with type 1 and type 2 
exacerbations are most likely to benefit from antibiotic therapy. Giving long term 
antibiotic treatment to a patient may have consequences; the development of 
antimicrobial resistance is by far the most important one. As the new emerging strains 
and the older strains develop emerging resistance pattern  to old classes of antibiotics 
it has become still more important to determine  antimicrobial sensitivity pattern. 
 
 Treatment should be worked towards three important goals particularly against 
bacterial infection:  
 
1. Prevention  of transient loss of pulmonary function 
2. Relief of symptoms  
3. To reassess the cause of disease to reduce the risk of further exacerbation 
 
 Drug treatment should always aim on decreasing the bacterial load, to prevent 
respiratory infection to decrease airway inflammation, to decrease work of breathing 
and to prevent further exacerbation ,to select proper and appropriate antibiotic therapy 
for flares of bacterial origin. 
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 The Antibiotics should be chosen as per patients affordability, severity of 
exacerbation, bacterial spectrum, the most important is to have the knowledge of local 
bacteriological profile and it’s sensitivity pattern especially prevalence of MRSA, 
ESBL, AmpC, MBL producers . 
 
 MDR are organisms which are resistant to 3 or more group of antibiotics with 
different mechanisms of action. Organisms isolated commonly with the following 
resistance  pattern-(43) 
 
1. Methicillin resistant staphylococcus aureus (MRSA) 
2. Beta lactamases producing GNB-ESBLs, AmpC, MBL 
3. Drug Resistance Streptococcus pneumoniae (DRSP). 
 
1. BETA LACTAMASES IN GRAM NEGATIVE BACILLI:(44,45) 
a) EXTENDED SPECTRUM BETA LACTAMASES (ESBL)  
 ESBL’s are  Bush class A plasmid mediated  βlactamases capable of 
hydrolysing Penicillins and Monobactams and inhibited by  βlactamase 
inhibitors(Clavulanic acid, Sulbactam, Tazobactam)  but have no detectable activity 
against Cephamycins or Carbapenems(Imipenem, Meropenem)  produced mainly by 
members of family  enterobacteriaceae(Klebsiella pneumonia,Klebsiella 
oxytoca,E.coli,Proteus mirabilis) and some non fermentors.They also exhibit carry 
resistance for other group of antibiotics(like aminoglycosides, fluroquinolones, 
cotrimoxazole etc) which actually narrowes down the choices of antibiotics available 
for treatment. 
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 Recent surveys have identified ESBLs in 70—90% of Enterobacteriaceae in 
India (105).Study done by SMART 2007 stated  ESBL rates in India for  Klebsiella 
pneumoniae, and Klebsiella oxytoca were , 69.4%, and 100%, respectively which is 
higher as compared to our study.(46) 
 
DETERMINATION METHODS FOR EXTENDED SPECTRUM 
BETALACTAMASES :(63) 
1. Screening methods: using cefotxime/Ceftriaxone cefpodoxime /ceftazidime/ 
aztreonam discs by disc diffusion method. 
2. CLSI phenotypic confirmatory methods: by broth microdilution method/disc 
diffusion method. 
3. Other methods: Inhibitor potentiated disc diffusion test,double disc diffusion 
synergy test, ESBL E test, automated methods. 
4. Molecular methods: PCR,DNA probes, PCR-RFLP,PCR-SSCP, Oligotyping, 
nucleotide sequencing. 
 
b) AmpC PRODUCTION IN GRAM NEGATIVE BACILLI:(48) 
 Amp C βlactamases are Bush class C β lactamases (plasmid or chromosomal 
mediated),that are resistant to all beta lactamases  (including  Cephamycins) and are 
poorly inhibited by beta lactamase inhibitor (Clavulanic acid)combinations except 
Carbapenems. 
 
 The main Amp C producing microbes are   Acinetobacter species and 
Klebsiella species. 
 
29 
 
 Multicentric study conducted in India by Laghawe et al showed that the 
prevalenc of Amp C producing GNB in india is 15.97% .(47) 
 
DETECTION METHODS FOR AmpC BETA LACTAMASES : (48) 
1. Screening methods: using cefoxitin disc by disc diffusion method, Cefoxitin 
agar method, Inhibitor based methods, AmpC disc test, Modified three 
dimensional test, Amp C β lactamase E test. 
2. Molecular methods: PCR based methods. 
 
c) METALLO BETA LACTAMASES IN GRAM NEGATIVE BACILLI :(49) 
 MBL are Bush class B  β lactamases capable of hydrolysing carbapenems, 
other β lactams and βlactamase inhibitors with the exception of aztreonam. They are 
predominantly found in Acinetobacter baumanii and Pseudomonas aeruginosa. 
Resistance to Carbapenems may be due to impermeability through  cell wall due to 
loss of omrD porin, up regulation of an active efflux system ,Carbapenemase 
production ,or production of MBL’s. In  Acinetobacter species and Pseudomonas 
aeruginosa  the prevalence of carbapenam resistance in various parts of our country 
was found to be 48-80% and 31 to 64% respectively.(50) 
 
DETECTION METHODS FOR MBL :(64) 
1. Screening methods:using carbapenem disc(imipenam, meropenam, ertapenam 
etc) 
2. Confirmatory methods: Imipenam –EDTA combined disc method, Imipenam 
EDTA double disc synergy test (DDST),EDTA disc potentiation test, HODGE 
test, MBL E test 
3. Molecular methods: PCR techniques 
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2. METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS: 
These are β lactamases which rendeer the organism resistance to all available 
βlactamases, βlactam/βlactamase inhibitor combinations, monobactams abd 
carbapenems. A study conducted by INSAR group ,showed that the prevalence of 
MRSA in our country is about 40 %.(51) 
 
Detection methods for MRSA (52): 
1. Screening methods: using cefoxitin/oxacillin disc by disc diffusion method 
2. Confirmatory methods:Oxacillin MIC detection (by broth dilution,agar 
dilution,E test method),Oxacillin screen agar 
3. Molecular methods:detection of mecA gene or PBP2protein(its protein 
product) 
 
3. DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE (53) 
 In the past, S. pneumoniae was almost uniformly susceptible to penicillin, 
allowing  most physicians to treat persons who had severe infections with penicillin 
alone without testing for resistance. Resistance to penicillin and other antimicrobial 
agents has spread rapidly and was first reported in Australia in 1967, in New Guinea 
in 1969, in South Africa in 1977, and in many other countries throughout Africa, Asia, 
and Europe.MDR strains resistant to penicillin, tetracycline, erythromycin, 
cotrimoxazole and chloramphenicol were identified.  
 
 Investigations of outbreaks by CDC  have revealed that Pneumococcal isolates 
resistance to penicillin in some areas of the United States, as many as 30%.(54) 
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 In a study conducted by Kurien  et al. Pneumococcal infection is found in the 
prevalence of about 53.90% in India, with resisitance strains ranging from 4%-
15.12%,in different parts of our country .(55) 
 
DETECTION METHODS FOR DRUG RESISTANT TREPTOCOCCUS 
PNEUMONIAE : (56) 
1. Screening method : by disc diffusion method using MHA supplemented by 5% 
sheep blood.Penicillin sensitivity is detected by using oxacillin (1μg) disc. 
2. Confirmatory methods: MIC detection methods – Isolates found to be 
nonsusceptible by oxacillin disk should then be subjected to quantitative MIC 
testing against penicillin. MIC detection methods –broth/agar dilution method,  
or antimicrobial gradient E strips using Mueller Hinton broth supplemented 
with lysed horse blood or defibrinated sheep blood. 
 
  
  
 
 
 
 
 
 
AIMS AND OBJECTIVES  
OF THE STUDY 
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AIMS AND OBJECTIVE 
 
 To identify the bacterial and fungal agents causing  acute exacerbation in 
COPD and in Stable COPD . 
 
 To compare the isolates between AECOPD and Stable COPD patients  
 
 To determine the antibacterial and antifungal susceptibility pattern  of the 
isolates in both the cases. 
 
  
  
 
MATERIALS AND   
METHODS 
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MATERIALS & METHODS 
 
 This study was conducted at the Institute of Microbiology, Madras Medical  
College in association with Departments of InternalMedicine, Thoracic Medicine, 
Intensive Medicare Care Unit at Rajiv Gandhi Government General Hospital, 
Chennai. This study samples were   selected as per GOLD criteria(14) . 
 
Study design & period: 
 Cross sectional study. One year (from October 2013 to September 2014) 
 
Study population: 
 The Study population consisted of   150 in patients presenting with signs and 
symptom of AECOPD and   50 stable COPD   out  patients. 
 
Ethical clearence: 
 Before the commencement of the study, approval was obtained from 
Institutional Ethical Committee. Informed consent was obtained from the study group. 
The  Patients  were interviewed with structured questionnaire. 
 
Inclusion criteria: 
 Patients  older than 18 years were selected  as per FEV1/FVC  and FEV1 with 
GOLD  criteria(14)  Among these the following patients were selected; 
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For  AECOPD as per Anthosien criteria (15) 
 Patients with  history of chronic bronchitis , emphysema, and small airway 
disease presenting with two of the  following symptoms of acute exacerbation 
such as: 
 Increased cough 
 Increased purulence and/or volume of expectorations 
 Increased severity of dyspnoea. 
 4.Fever and Leucocytosis  
 
For Stable COPD patients 
 Patients  with history of  COPD visiting OPD without the above symptoms of 
AECOPD were included in the Stable group. 
 
Exclusion criteria: 
 Patients   with   asthma, interstitial lung disease, present or past history of 
tuberculosis and  all cases who had evidence of pneumonia or bronchiectasis 
clinically or on chest radiography (PA view) which developed as a sequelae to 
other disease. 
 Exacerbation due to noninfectious causes (pulmonary thromboembolism, air 
pollutants). 
 Patients already taking antibiotics for past 24 hrs . 
 
Collection of data: 
 Data were collected from patients who satisfied the inclusion criteria, using 
preformed structured questionnaire. Demographic details like name, age sex, 
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address,date of admission, clinical data like presenting complaints, personal history, 
past medical history, history suggestive ofimmunization , chest radiographic findings, 
physical examination findings  and details of clinical diagnosis were collected. 
 
 Basic blood investigation such as   Haemoglobin estimation, Total leukocyte 
count, Differential count,ESR,Blood glucose level,Blood urea and Serum creatinine 
levels were documented. 
 
Sample collection and Transport: 
 All the samples were collected under strict aseptic precautions in sterile 
containers, properly labelled and were transported to the laboratory in appropriate 
conditions and processed within one hour of collection. 
 
Samples collected: 
1) Sputum (expectorated /induced) 
2) Bronchial wash 
3) Endotracheal aspirate 
4) Blood 
 
Procedure of collection &transportation of samples(21,106,109) 
1a) Expectorated Sputum: 
 The patient was instructed regarding the method of using the sterile sputum 
cups and the importance of collecting  deeply coughed specimen. Patients were 
instructed to brush their teeth , rinse their mouth with saline or water, just before 
collecting sputum sample.  Early morning sputum samples were collected under direct 
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supervision even before the patient had any food intake. Samples were taken to the 
laboratory for processing, within 1 hour of collection. 
 
1b) Induced sputum: 
 These samples (aerosol induced specimen) were collected after allowing the 
patients to inhale aerosolized droplets of solution containing 15% sodium chloride for 
10 minutes or until a strong cough reflex is induced. The samples were collected in 
sterile sputum cups and were taken to the laboratory for processing, as soon as 
possible. 
 
2) Bronchial wash: 
 These samples were collected when the pulmonologist, via a fiber optic 
bronchoscope, was not able to visualize purulent secretions or diseased part of the 
lung segment. Small amounts of physiological saline were infused and the reaspirated 
sample is collected into the sterile container for further processing. 
 
3) Endotracheal aspirate: 
 The fraction of inspired oxygen was set at 90% or more. None of the patients 
received local anesthetics. A blind endotracheal aspiration sample was obtained first 
by sterile means using a 22-inch suction catheter and collected in a mucus collector 
(Specimen trap) for patients with endotracheal tube. 
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4) Blood: 
 With strict aseptic precautions 10ml of blood sample was collected into a 
sterile screw capped blood culture bottle containing 50 ml of sterile Trypticase Soy 
Broth. 
 
Direct Microscopy: 
 All the respiratory samples like sputum, bronchial wash,Endotracheal aspirate 
were subjected to the following microscopic examination as per Standard Operating 
Procedures. 
 
 10% potassium hydroxide mount-to detect the presence of fungal elements 
 Gram’s stain-to detect the presence of bacterial cells, their gram reaction, 
morphology, arrangement and also to detect fungal elements 
 Acid Fast stain-to detect the presence of Mycobacterium tuberculosis bacilli in 
the Sample 
 
Processing of sample and Culture :  (35-37) 
1) Sputum: (55,39,56 ) 
 A few glass beads (2.5-3.5 mm) and an equal volume of 2% (w/v) N-acetyl-l-
cysteine (NAC) were added to each specimen. The NAC solution was freshly 
prepared each day by dissolving 2 g NAC in 13 ml 1N NaOH and diluting to a final 
volume of 100 ml with PBS. The pH of the solution was adjusted to 7.3 . The caps on 
the universal containers were securely tightened, the NAC-sputum mixtures were 
agitated on a vortex mixer for 10 seconds, allowed to stand at room temperature for 10 
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minutes, and finally vortex mixed for a further 15 seconds. Homogenised sputa were 
processed within 30 minutes. 
 
 All the sputum samples were prescreened with Gram’s stain , using Bartlett 
scoring system. Only those samples which met the acceptance criteria (a final score 0f 
>0) were   further processed for culture. Rest of the samples was  discarded and repeat 
sample was obtained in all possible cases. 
 
 Sputum  samples were mechanically homogenized with sterile glass beads 
using vortex machine. Tenfold serial dilutions of the homogenised sample were made 
in brain heart infusion broth and with 0.01 ml loop  were plated out onto the surface of 
a range of different media including blood agar, chocolate agar, MacConkey agar.  
 
 MacConkey agar plate, at 37 oC in ambient air for 24 hrs 
 5% sheep Blood agar plate, with  5-10% Co2, 37 o C for 24 hrs 
 Chocholate agar plate ,with  5-10% Co2, 37 o C for 24 hrs 
 5% Horse chocolate agar plate, with  5-10% CO2, at 370 C for 24 hrs 
 
Horse Blood Collection: 
 Horse was brought to plasmapheresis block and name,group,bleeding date were 
verified before bleeding. Jugular vein was raised by means of a neck rope .The area at 
the site of jugular furrow was shaved and sterilised .A cannula of 10G autoclaved 
needle is inserted into the vein .The blood was collected by using sterilised 5L/10L 
glass bottle with 30-40 glass beads. 
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 (As per CPCSEA norm – Blood collected as per body weight of animal :0-5% 
of body wt every 2 wks with plasmapheresis or 1.5% of body wt for every 4 wks with 
plasmapheresis  ie 300ml) 
 
 After i ncubation, bacterial colonies were counted .The number of colony 
forming units/ml sputum was calculated from the number of colonies obtained and the 
dilution of the sputum.  
 
Evaluation of bacterial culture plates: 
 Colonies grown on cultured plates were evaluated at 24 and 48 hrs 
 
a) Detection of Colony Forming Units in the sample:(38) 
 After the specified period and condition of incubation, the number of colonies  
grown in the culture plate is counted and the CFU/ml in the original sample was 
calculated using the following formula, 
 
 CFU/ml=number of colonies X dilution factor  
 CFU >106/ml was accepted as potential pathogen except for Streptococcus 
pneumoniae   CFU >105/ml was considered as significant. 
 
 Induced sputum sample was accepted for culture without prescreening , as they 
usually contain material directly from alveolar spaces with very little contamination 
from upper respiratory secretions . 
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2) Bronchial wash: 
 These samples were concentrated by centrifugation and the sediment were used 
for Gram staining and culture. Prescreening is not done for these samples,as they 
contain lower respiratory tract material. 
 
3) Endotracheal Aspirate(EA)(57): 
 Endotracheal aspirate samples were mechanically liquefied and homogenized 
by vortexing for 1 min with glass beads, followed by centrifuging at 3,000 rpm for 10 
min .EA cultures were quantified using calibrated loops.  100-fold diluted EA were 
evenly streaked with 1 µl loop on entire surface of a chocolate agar plate, a sheep 
blood agar plate, and a MacConkey agar plate. Plates are incubated overnight in a 5% 
CO2 atmosphere at 35°C. Colonies were then counted and bacterial concentrations 
(cfu/mL) were calculated. Microorganisms with counts > 104 cfu/mL were submitted 
for identification and antimicrobial susceptibility testing. If no growth was detected on 
any plate, the incubation was extended for 24 hr. 
  
4) Blood: 
 Blood sample along with Trypticase Soy Broth in blood culture bottle is 
incubated for 24 hrs at 37oC and then further subcultured onto specific media plates. 
 
 For fungal culture the samples were inoculated into two sets of   culture media-
Sabouraud’s  Dextrose agar (SDA) with cycloheximide and antibiotics, 
incubated at 25°C and  at 37°C,for upto 4 weeks. 
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b) Interpretation of bacterial cultures: 
 The isolated colonies were identified by means of Gram’s stain, motility, 
catalase test, oxidase test, coagulase test and by  of various other biochemical 
reactions  like Indole test, Methyl red test, Voges proskauer test, Citrate utilisation 
test, Urease test, Triple sugar iron agar, Nitrate reduction test, Hugh-Leifsons 
oxidation fermentation test, coagulase production (for Staphylococcus), Optochin 
Sensitivity (for Streptococcus pneumoniae)were performed. Sugar fermentation tests 
with sugars viz: Glucose, Lactose, Sucrose, Maltose, Mannitol, Xylose, Arabinose and 
Dulcitol, inositols  etc were done to identify the isolate according to standard 
laboratory procedures. 
 
c) Interpretation of fungal cultures: 
 Inoculated SDA slants were inspected daily for first one week and then twice 
weekly for the next 3 weeks. Filamentous fungal isolates were identified by LPCB 
mount preparation, based on the hyphal and conidial arrangement and morphology. 
 
Antimicrobial susceptibility testing : (58) 
 Done to identify the sensitivity and resistant patterns of all isolates according to 
CLSI guidelines. 
 
Non fastidious organisms(59,60): 
 Antimicrobial susceptibility testing was done by disc diffusion method using 
Kirby bauer technique on Mueller Hinton agar (HiMedia,Mumbai) ,using appropriate 
antimicrobial drugs as directed by CLSI guidelines.  
 
42 
 
 Inoculum: Growth method suspension, equivalent to a 0.5 McFarland standard 
Incubation: 35 ± 2 °C; ambient air ,for 16 to 18 hours 
 Quality control tests were done every week for testing the performance of 
media & drugs using the following standard ATCC control strains. 
 
ATCC control strains: 
 Staphylococcus aureus–ATCC 25923 
 Escherichia coli-ATCC 25922 
 Pseudomonas aeruginosa-ATCC 27853 
 Klebsiella pneumoniae (ESBL)-ATCC 700603 
 
 Interpretation of Zone of inhibition diameters were done according to CLSI 
guidelines. 
 
Fastidious organism(61,62): 
 Antimicrobial susceptibility testing was done by disc diffusion method using 
Kirby bauer technique on Mueller Hinton agar supplemented with 5% sheep blood , 
using antimicrobial drugs ,as directed by CLSI guidelines . 
 
 Inoculum: Direct colony suspension, equivalent to a 0.5 McFarland standard 
 Incubation: 35 ± 2 °C; in 5% CO2 for 20 to 24 hours 
 
 Quality control tests were done every week for testing the performance of 
media & drugs using the standard Streptococcus pneumonia  ATCC49619 control 
strain. 
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 Interpretation of Zone of inhibition diameters were done according to CLSI 
guidelines for all isolates . 
 
Panel of antibiotics included for testing antimicrobial sensitivity of Gram 
negative bacilli. 
Antibiotic 
Disc 
content in 
µg 
Gram Negative 
Bacilli 
Diameter of Zone of Inhibition  
in mm  Break points 
Sensitive Intermediate Resistant
Amikacin 30  ≥17 15-16 ≤14 
Cefotaxime 30 
Enterobacteriaceae ≥26 
≥23 
23-25 
15-22 
≤22 
≤14 Acinetobacter 
Ceftazidime 30 
Enterobacteriaceae ≥21 
≥18 
 
18-20 
15-17 
≤17 
≤14 
 
Acinetobacter 
P.aeruginosa
Cotrimoxazole 1.25/23.75  ≥16 11-15 ≤10 
Ciprofloxacin 5  ≥31 21-30 ≤20 
Gentamicin 10  ≥15 13-14 ≤12 
Imipenem 10 
Enterobacteriaceae
≥23 
≥19 
≥22 
20-22 
16-18 
 
19-21 
≤19 
≤15 
≤18 
P.aeruginosa 
Acinetobacter 
Piperacillin- 
Tazobactam 
100/10 
 
 
Enterobacteriaceae
Acinetobacter 
P.aeruginosa 
≥21 
 
≥21 
18-20 
 
 
15-20 
≤17 
 
 
≤14 
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Panel of antibiotics included for testing antimicrobial sensitivity of Gram positive 
and Gram Negative Cocci. 
 
Antibiotic 
Disc 
content   
µg 
Organisms 
Diameter of Zone of Inhibition 
in mm  Break points 
Sensitive Intermediate Resistant 
Amikacin 30  ≥17 15-16 ≤14 
Penicillin 10units Staphylococcus aureus 
≥29 
 - 
≤28 
 
Amoxycillinclavulanic 
acid 20/10 
Moraxella 
catarrhalis ≥20 - ≤19 
Ciprofloxacin 5  ≥21 16-20 ≤15 
Cotrimoxazole 
1.25 / 
23.75 
 
Staphylococcus 
aureus ≥16 
≥19 
11-15 
16-18 
≤10 
≤15 S.pneumoniae 
Cefotaxime 30 Streptococcus sp. ≥24 -  
- 
 
Chloramphenicol 30 
S.pneumoniae ≥21 
≥21 
- 
18-20 
≤20 
≤17 Streptococcus sp 
Cefoxitin 30 Staphylococcus aureus ≥22 - ≤21 
Erythromycin 15 
Staphylococcus 
aureus ≥23 14-22 ≤13 
S.pneumoniae ≥21 16-20 ≤15 
Ofloxacin 5 S.pneumoniae ≥16 13-15 ≤12 
Oxacillin 1 S.pneumoniae ≥20 - - 
Optochin 5 S.pneumoniae ≥14 - <14 
Tetracycline 30 
Staphylococcus 
aureus ≥19 15-18 ≤14 
S.pneumoniae ≥28 25-27 ≤24 
Vancomycin 30 S.pneumoniae ≥17 - - 
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Methods of detection of β lactamase production among gram negative bacilli: 
 
A)Extended Spectrum β Lactamase - detection methods : (44,45) 
1)Screening test: 
 Gram negative bacilli isolates showing the following zone of inhibition 
diameters  to the  respective drugs were considered to be possible ESBL producers. 
 
Antibiotic Break point zone diameter for possible ESBL strains 
                   Cefotaxime(30μg) ≤27 mm 
                   Ceftazidime(30μg) ≤22 mm 
 
2) Phenotypic  confirmatory method: 
 To 5ml of nutrient broth , 3-5 colonies of isolates grown on a non selective 
culture medium was  added and incubated for 2-4 hrs at 35o C and the resulting 
turbidity is matched with 0.5 Mcfarlands standard. The test was lawn cultured onto 
Cation adjusted MHA Plate(HiMedia,Mumbai). Ceftazidime (30μg) disc and 
Ceftazidime/Clavulanic acid disc  (30μg/10μg) (Himedia, Mumbai) were placed on 
the surface of the plate and incubated overnight at 350 C. A ≥ 5mm increase in zone 
diameter  for Ceftazidime tested in combination with  Clavulanic acid versus its zone 
when tested alone confirmed an ESBL producing organism. 
 
3) Double disk diffusion synergy test: 
 On a lawn culture of 0.5 Mcfarlands test lsolate on Cation adjusted MHA plate, 
Augmentin disc(Amoxycillin Clavulanic Acid)  was placed in the centre of the plate 
and a disc of  Ceftazidime (Himedia, Mumbai) was  kept 30mm apart from centre to 
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centre .After incubation , a clear increase in the zone of inhibition  towards Augmentin 
disc was interpreted as positive for ESBL production. 
  
B)AmpC β lactamases detection methods : (48) 
1) Screening method: 
 A lawn culture of 0.5 Mcfarland suspension of test isolate was made on Cation 
adjusted MHA plate. Ceftazidime (30μg) disc were placed adjacent to Cefoxitin 
(30μg) disc at a distance of 20 mm from each other. After overnight incubation at 350 
C, isolates showing blunting of Ceftazidime zone of inhibition adjacent to Cefoxitin 
disc or showing reduced  susceptibility to Ceftazidime and Cefoxitin were considered 
as screen positive. 
 
2) AmpC disc test : 
 On a Cation adjusted MHA plate ,lawn culture of ATCC E.coli 25922 was 
prepared.On a 6mm sterile disc ,which are moistened with sterile saline, several 
colonies of test organism were inoculated. The inoculated disc was then placed beside 
a Cefoxitin disc (30μg) (almost touching) on the inoculated plate. After incubation, 
flattening or indentation of the Cefoxitin inhibition zone in the vicinity of the test disc 
were considered as AmpC positive isolate. 
 
C) Metallo β lactamase (MBL) detection methods : (49) 
1) Imipenem- EDTA  double disc synergy test(DDST): 
 The organism was inoculated onto Cation adjusted MHA plates as 
recommended by the CLSI  .A 10 μg Imipenem disc was placed 20mm centre to 
centre from a blank disc containing 10µl of EDTA .After incubation there was 
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enhancement of zone of inhibition in the area between Imipenem and EDTA as 
compared to the  zone of inhibition on the far side of drug was interpreted as positive. 
 
2) Imipenem –EDTA combined disc test: 
 Imipenem 10μg and 10μg Imipenem disc containing 750μg of EDTA solution, 
were placed on a lawn culture of test organism on Cation adjusted Muller Hinton Agar 
plate and incubated overnight. If the increase in inhibition zone with Imipenem- 
EDTA disc was   ≥ 7mm than the Imipenem disc alone, it was considered MBL 
positive. 
 
1) Screening and confirmatory test for suspected carbapenase production: (64) 
A) Initial screen test :  
 0.5 Mcfarland’s suspension of test isolate was lawn cultured on cation adjusted 
MHA plates. 10 μg Meropenem  disc was  placed on the surface of lawn culture, 
incubated at 33–35 °C; in ambient air for 16–18 hours. 
 
Interpretation : Meropenem 16-21mm 
 The zone diameter of inhibition indicates Carbapenamase  production and was  
confirmed by Modified Hodge test. 
 
B) Phenotypic confirmatory test: Modified Hodge test(MHT) 
 It is a phenotypic confirmatory test for Carbapenemase  production in 
Enterobacteriaceae. 
 
 The Confirmatory test recommendations are largely derived from US isolates 
of  Enterobacteriaceae ,and provide a high level of Sensitivity(>90%) and  specificity 
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(>90%) in detecting KPC-type carbapenemase  in these isolates .No data exist on the 
usefulness of these tests for the detection of Carbapenemase production in non-
fermenting gram –negative bacilli. 
 
Method: 
 0.5 Mcfarland’s suspension of ATCC E.coli 25922 isolate in broth or saline 
,and dilute 1:10 in saline or broth   was lawn cultured on cation adjusted MHA plates. 
10 μg Meropenem  disc was  placed on the surface of lawn culture .With 10 µl loop 3-
5 colonies of positive control Klebsiella pneumoniae ATCC –BAA-1705 ,of negative 
control  Klebsiella pneumoniae ATCC –BAA-1706  and of test isolates grown 
overnight on Blood agar plate were inoculated  in a  straight line out from the edge of 
the disc .The streak length of 20-25mm were made. Incubated at 33–35 °C; in ambient 
air for 16–18 hours. 
 
 Interpretation : The presence of distorted zone of inhibition  was interpretated 
as positive for Carbapenemase  production. 
 
 Note :Not all Carbapenemase  producing  isolates  of  Enterobacteriaceae are 
MHT positive and MHT –positive results may be encountered in isolates with 
Carbapenem resistance mechanisms other than  Carbapenemase  production. 
 
  
49 
 
Methicillin resistance detection in Staphylococcus aureus  : (65) 
Disc diffusion method: 
 0.5 Mcfarland’s suspension of test isolate was lawn cultured on MHA plates.30 
μg cefoxitin disc is placed on the surface of lawn culture ,incubated at 33–35 °C; in 
ambient air for 16–18 hours.Isolates showing inhibition zone diameter ≥22 mm ,were 
considered as Methicillin sensitive strains and those that show inhibition zone 
diameter ≤21 mm ,were considered as Methicillin resistant isolates. 
 
Detection of Vancomycin MIC for Staphylococcus aureus isolates by macrobroth 
dilution methods :(104) 
Cation adjusted Mueller Hinton broth.(pH 7.2-7.4) 
Media Preparation of stock antibiotic solution: 
 
                Formula:                   1000   x     V    x   C  
                               W=           ----------------------------- 
                                                             P 
where 
W = weight of the antibiotic to be dissolved in the volume V 
V = volume of the stock solution to be prepared (10ml) 
C =final concentration of the antibiotic solution (1024μg/ml) 
p= potency of the antibiotic in relation to the base. (For vancomycin, p= 
950/1000 mg; Himedia) 
10.8mg of meropenam drug was dissolved in 10ml of distilled water to prepare 
a stock solution concentration of 1024µg 
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Preparing dilution of antibiotics: 
 Arrange  two rows of sterile test tubes (1 row for the test & 2nd for ATCC 
 control from conc 1024-0.0625 μg/ml) 
 Using sterile pipette  put 1ml cation adjusted MH broth in each  12 test tubes of 
both ATCC control and test . 
 Take  1ml from stock solution and put it in 1 st  test tube of both control and test  
 Then take 1ml from 1st  test tube to the 2nd test tube and repeat  this procedure 
of two fold serial dilution  till the 12th tube . 
 Place 1 ml of the antibiotic free broth in the last tube in each row (growth 
control) 
 The sterility controls for the antibiotic solution was also  kept. 
 
Inoculum preparation for the test and ATCC control and incubation: 
 To 9.9 ml of MH broth in a test tube , add 0.1 ml of 0.5 Mcfarland turbidity 
matched test organism. 
 Mix well, transfer 1 ml of inoculum using 2 ml pipette to each tube containing 
antibiotic dilutions and also to the control tube. 
 Similarly repeat the procedure for ATCC control strain  
 Incubate the rack at 37 0C  for 24hrs 
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Observation &Interpretation: 
 Observe the MIC of ATCC control strain, If it is out of the sensitive range, then 
test is invalid. 
 If MIC of ATCC strain is in the sensitive range then read for the test organism 
 The lowest concentration of the antibiotic in which there is no visible growth 
will be the MIC for the drug & for the test organism. 
 
Interpretation criteria: MIC values for  Vancomycin was interpreted as follows: 
MIC ≤ 2μ/ml   -  Sensitive. 
 MIC : 4-8 μg/ml  - Intermediate  
 MIC : ≥16μg/ml - Resistant 
 
Detection of MIC by microbroth dilution method, for Meropenem ,in case of 
drug resistant Enterobacteriaceae and Non Enterobacteriaceae -isolates  (104): 
 
Culture media: Cation adjusted Mueller Hinton broth (pH 7.2-7.4) 
 
Preparation of stock antibiotic solution: 
Formula: 
                          W =          1000 x V x C 
                                       --------------------------- 
                                                     P 
   where                                                         
W = weight of the antibiotic to be dissolved in the volume V 
V = volume of the stock solution to be prepared (10ml) 
C =final concentration of the antibiotic solution 
p= potency of the antibiotic in relation to the base 
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Potency of Meropenam=675/1000mg 
15.2mg of meropenam drug was dissolved in 10ml of distilled water to prepare 
a stock solution concentration of 1024µg/ml 
 
Preparing dilution of antibiotics: 
 Arrange  two rows of sterile test tubes (1 row for the test & 2nd for ATCC 
 control from conc 1024-0.0625 μg/ml) 
 Using sterile pipette  put 1ml cation adjusted MH broth in each  12 test tubes of 
both ATCC control and test . 
 Take   1ml from stock solution and put it in 1 st  test tube of both control and 
test . 
 Then take 1ml from 1st  test tube to the 2nd test tube and repeat  this procedure 
of two fold serial dilution  till the 12th tube . 
 Place 1 ml of the antibiotic free broth in the last tube in each row (growth 
control) 
 The sterility controls for the antibiotic solution was also   kept. 
 
Inoculum preparation for the test and ATCC control and incubation: 
 To 9.9 ml of MH broth in a test  tube  , add 0.1 ml of 0.5 Mcfarland turbidity 
matched test organism. 
 Mix well, transfer 1 ml of inoculum using 2 ml pipette to each tube containing 
antibiotic dilutions and also to the control tube. 
 Similarly repeat the procedure for ATCC control strain  
 Incubate the rack at 37 0C  for 16-20hrs 
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Observation &Interpretation: 
 Observe the MIC of ATCC control strain, If  it is out of the sensitive range, 
then test is invalid. 
 If MIC of ATCC strain is in the sensitive range then read for the test organism 
 The lowest concentration of the antibiotic in which there is no visible growth 
will be the MIC for the drug & for the test organism. 
 
Interpretation criteria: for Meropenam MIC values Enterobacteriaceae 
 MIC ≤1μg/ml –sensitive. 
 MIC :2 μg/ml –Intermediate  
 MIC :≥4μg/ml-resistant 
 
Meropenam MIC values for Non- Enterobacteriaceae 
 MIC: ≤2μg/ml –sensitive. 
 MIC :4μg/ml –Intermediate  
 MIC :≥8μg/ml-resistant 
 
Drug resistant Streptococcus pneumoniae :  (98.103) 
1. Screening method : by disc diffusion method using MHA supplemented by 5% 
sheep blood. Penicillin sensitivity is detected by using oxacillin (1μg) disc 
 
2. Confirmatory methods: Isolates found to be nonsusceptible by oxacillin disk 
should then be subjected to quantitative MIC testing against penicillin. MIC 
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detection methods –broth/agar dilution method,  or antimicrobial gradient E 
strips using Mueller Hinton broth supplemented with lysed horse blood or 
defibrinated sheep blood. 
 
Note :  a) For fastidious organisms,if the diameter of the zone of inhibition falls 
within the resistant range,ie ≤19mm it is confirmed by MIC detection for the 
concerned drugs before reporting it as resistant, as per CLSI guidelines. 
b) Penicillin susceptibility were detected by using Oxacillin(1μg) disc. A zone 
diameter of ≥20mm for oxacillin is taken as penicillin susceptible strains . 
 
Method: 
Detection of Penicillin Minimum inhibitory concentration  for Streptococcus 
pneumoniae isolates by Epsilometer test (E test) in case of resistance to Oxacillin 
disc: (98) 
 Streptococcus pneumoniae  was grown overnight on blood agar plates, 
suspended in Trypticase soy broth to a 0.5 MacFarland density, and inoculated for 
confluent growth onto Mueller-Hinton-blood agar plates. Penicillin E test strips were 
applied to the plates after the inoculum had dried for 15 min. The penicillin E test 
strips used had a MIC range of 0.002 to 32 ,ug/ml. Incubation was at 35°C, under 5% 
CO2 for 18 to 24 h. The MICs were read at the point of intersection between the edge 
of the zone of bacterial growth and the E test strip, per manufacturer's instructions.  
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MIC Observation and interpretation as follows: 
  MIC  ≤0.06 µg/ml- Sensitive 
   0.12-1 µg/ml-Intermediate 
   ≥2µg/ml- Resistant 
 
STATISTICAL ANALYSIS: 
 Statistical  analysis was done by using statistical package for social 
sciences(SPSS)  version 21.The test used in this study was Pearson’s Chi square 
analysis test.P value less than <0.05 is considered as stastically significant. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
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RESULTS 
 
 This Cross sectional study was conducted at the Institute of Microbiology, 
Madras Medical College in association with Departments of Thoracic 
Medicine,Internal Medicine and Intensive Care Unit at the Rajiv Gandhi Government 
General Hospital, Chennai. A total of 200 patients were included in the study who 
were  categorized into two groups-150 AECOPD and 50 Stable COPD patients. None 
of the patients had received immunization for Haemophilus influenzae or 
Streptococcus pneumoniae in the past. 
 
TABLE 1 : AGE AND SEX DISTRIBUTION OF AECOPD (n=150) 
AGE IN YEARS MALE FEMALE TOTAL PERCENTAGE
40-50 18 1 19 12.7% 
51-60 35 9 44 29.4% 
61-70 37 8 45 30% 
71-80 23 6 29 19.3% 
81-90 11 2 13 8.6% 
TOTAL 124(82.7%) 26(17.3%) 150 100% 
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 In AECOPD the study group consisted of predominantly males with a 
male:female ratio 62:23.  
male
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Sex Distribution of AECOPD patients
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Age and Sex distribution of AECOPD patients
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TABLE 2 : AGE AND SEX DISTRIBUTION OF STABLE COPD PATIENTS (n=50) 
AGE IN 
YEARS MALE FEMALE TOTAL PERCENTAGE
31-40 2 0 2 4% 
41-50 4 1 5 10% 
51-60 16 2 18 36% 
61-70 16 5 21 42% 
71-80 4 - 4 8% 
TOTAL 42(84%) 8(16%) 50 100% 
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In stable COPD the study group consisted of predominantly males with a ratio of 21:4  
 
TABLE 3: ASSOCIATION OF SMOKING AS THE  RISK FACTORS OF 
COPD AMONG STUDY GROUP 
   
AECOPD n=150 Stable COPD n=50 
No % no % 
1 Smoking 122 81.3 42 84 
2 Non -smoking 28 18.7 8 16 
 
 Smoking was associated with AECOPD in 81.3% of cases and 84% in COPD 
patients. There was  statistical significance P value <0.001. 
  
84%
16%
Sex Distribution in stable COPD
male
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TABLE 4: ASSOCIATION OF OCCUPATION AS RISK FACTORS OF COPD 
AMONG STUDY GROUP 
  
AECOPD 
n=150 
COPD 
n=50 
No % No % 
1. Biogas inhalation during cooking/burning fire 26 17.3 8 16 
2. Carpenter 1 0.6 - - 
3 Aluminium worker 1 0.6 1 2 
 
 Biogas inhalation was associated with AECOPD in 17.3% of cases and 16% 
among COPD cases. Occupation as a risk factor was found in 6% of cases in 
AECOPD and 2% in Stable COPD. There was no Statistical significance  
 
ANALYSIS OF CAUSES OF COPD IN AECOPD PATIENTS
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Aluminium worker
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TABLE 5 : DISTRIBUTION OF STUDY POPULATION AS PER CLINICAL 
DIAGNOSIS 
AECOPD n=150 STABLE COPD n=50 
TYPE No % No % 
EMPHYSEMA 7 4.6 3 6 
CHRONIC 
BRONCHITIS 143 95.3 47 94 
 
 Chronic bronchitis was the most common condition in both stable (95.3%) and 
acute exacerbation(94%) of COPD. 
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TABLE 6: ANALYSIS OF SYMPTOMS OF PATIENTS WITH AECOPD 
(n=150 ) 
 
S. No Symptoms No % 
1 Increased Sputum volume 120 80% 
2 Increased Sputum purulence  109              72.6% 
3 Increased degree of Breathlessness 150 100% 
4 Fever>38  C 20 13.3% 
5 Increased wheeze/crepitations  150 100% 
  
 Increased level of breathlessness and wheeze were  the commonest symptom  
among patients with AECOPD(100%) followed by  sputum volume(80%),and sputum 
purulence(72.6%) 
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TABLE 7: CATOGERISATION OF AECOPD PATIENTS AS PER 
ANTHOSIEN CRITERIA(15) 
 
Type of exacerbation no % 
Type 1 109 72.6 
Type 2 11 7.3 
Type 3 30 20 
 
As per Anthosien criteria  Type 1 exacerbation was the most common (72.6%) 
with all three cardinal symptoms  followed by  Type3 exacerbation(20%). 
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TABLE 8 : COMPLICATIONS  ASSOCIATED  WITH   
AECOPD PATIENTS (n=150) 
 
S.no Complication No % 
1. Cor pulmonale 11 7.3 
2. Respiratory failure type 1 12 8 
3. Respiratory failure type 2 4 2.6 
4. Bacteremia 9 6 
 Total 36 24 
 
 
 Complications were observed in  36 (24%) patients among AECOPD patients 
among which Respiratory failure  (8%) was the most common complication followed 
by Corpulmonale (7.3%) and Bacteremia (6%).Stable COPD study group was not 
associated with any  complications. 
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TABLE 9: CATEGORISATION OF PATIENTS BY GOLD(1) CRITERIA FOR 
SEVERITY AMONG STUDY GROUP 
 AECOPD n=150 
Stable COPD 
n=50 
Type No % No % 
Mild 4 2.6 9 18 
Moderate 86 57.3 41 82 
Severe 60 40 - - 
 Among AECOPD patients, 57.3% of patients had moderately severe condition  
followed  by  Severe type (40%).Among Stable COPD patients most common type 
was moderate type 41(82%) followed by Mild type 9(18%). 
TABLE 10: DISTRIBUTION OF CULTURE POSITIVITY IN DIFFERENT 
SAMPLES 
RESPIRATORY 
 
SAMPLES 
Sample no (%) Culture positive % 
SPUTUM 119(79.3%) 77(64.7%) 
INDUCED 
SPUTUM 9 (6%) 8(88%) 
BRONCHIAL 
WASH 10(6.6%) 10(100%) 
ENDOTRACHEAL 
ASPIRATE 12(8%) 11(91.6%) 
TOTAL 150 106(70.6%) 
BLOOD BLOOD 150 9(6%) 
 The most common sample obtained was  Sputum(79.3%) in which culture 
positivity was 64.7%.Bronchial wash  and Endotracheal aspirates had the highest 
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culture positivity rate of 100% and 91.6% respectively.Bacteremia was observed in 
6% of patients. 
DISTRIBUTION OF SAMPLE TYPES 
 
                  
 
DISTRIBUTION OF CULTURE POSITIVITY IN RESPIRATORY  
AND BLOOD SAMPLES 
 
 Among respiratory samples 106 (70.6%) patients had culture positivity.6% of 
the patients with AECOPD had Bacteremia. 
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TABLE 11: DISTRIBUTION OF PATHOGENS AMONG  AECOPD 
PATIENTS FROM RESPIRATORY SAMPLES 
 
Types and combination of 
pathogens isolated 
Culture positive isolates n= 106 
 
No % 
Monobacterial 102 96.2 
Polybacterial 4 3.8 
Total 106 100 
 
 Monobacterial growth was observed in 96.2%.Two or more organisms was 
isolated in 3.8% of cases. 
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TABLE 12: DISTRIBUTION OF SINGLE   BACTERIAL ISOLATES FROM 
RESPIRATORY AND BLOOD SAMPLES IN AECOPD CASES 
 
Sample 
Gram positive isolates Gram negative isolates 
No % No % 
Respiratory samples 
n=102 23 22.5 79 77.5 
Blood samples 
n=9 4 44.5 5 55.5 
 
 Gram negative  bacteria were isolated in 79(77.4%) patients while  Gram 
positive bacteria were isolated  in 23(22.5%)  cases from respiratory samples.Gram 
negative  bacteria were isolated in 5(55.5%)  while  Gram positive bacteria were 
isolated  in 4(44.5%) cases from blood cultures. 
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Table 13: ASSOCIATION OF SPUTUM PURULENCE WITH CULTURE 
POSITIVITY IN AECOPD PATIENTS  
Type of sputum Culture positivity Culture negativity 
Purulent 
Sputum n=109 75 4 
Non purulent 
Sputum n=41 2 38 
 
 Culture positivity was significantly higher in patients with purulent sputum as 
compared  to nonpurulent  sputum. (P <0.001,Chi Square test)  
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TABLE 14: SPECIES DISTRIBUTION OF MONOBACTERIAL CULTURE 
POSITIVITY AMONG  RESPIRATORY SAMPLES IN  
AECOPD PATIENTS  (n=102) 
Sample S.
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Sputum 14 6 26 6 17 4 3 
Induced 
Sputum 1 - 2 1 1 1 - 
Bronchial 
Wash - - 3 - 3 4 - 
Endotracheal 
aspirate 1 1 3 - - 1 - 
Total 16 (15.6%) 
7 
(6.8%) 
34 
(33.3%) 
7 
(6.8%)
24 
(23.5%) 
11 
(10.7%) 
3 
(2.9%) 
 
 The most common pathogen isolated in sputum, induced sputum and 
endotracheal aspirate  was  Klebsiella pneumoniae(33.3%) followed by  Pseudomonas 
aeruginosa 24(23.5%). This was statistically analysed by Chisquare test. P value was 
<0.001 which was significant. 
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SPECIES DISTRIBUTION OF MONOBACTERIAL CULTURE POSITIVITY 
AMONG  RESPIRATORY SAMPLES IN  
AECOPD PATIENTS  (n=102) 
 
TABLE15: DISTRIBUTION OF MIXED INFECTION OF MICROBIAL 
ISOLATES AMONG RESPIRATORY SAMPLES 
 
Sample 
Klebsiella oxytoca 
+ 
Acinetobacter baumanii 
Klebsiella pneumoniae 
+ 
Pseudomonas aeruginosa 
 
Sputum - 1 
Endotracheal aspirate 1 2 
 
Mixed infection was found in 3 endotracheal aspirate and a single sputum  sample. 
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TABLE16: DISTRIBUTION OF  ISOLATES AMONG VARIOUS 
CATEGORIES OF AECOPD FROM RESPIRATORY SAMPLES(n=110) 
 
Organism isolated Mild Moderate Severe 
Staphylococcus aureus 
n=16 1(0.9%) 12(10.9%) 3(2.7%) 
Streptococcus pneumoniae 
n=7 - 2(1.8%) 5(4.5%) 
Klebsiella pneumoniae 
n=37 - 25(22.7%) 12(10.9%) 
Klebsiella oxytoca 
n=8 - 6(5.5%) 2(1.8%) 
Pseudomonas aeruginosa 
n=27 - 4(3.6%) 23(20.9%) 
Acinetobacter baumanii 
n=12 -  12(10.9%) 
Moraxella catarrhalis 
n=3 - 3(2.7%)  
 
 In moderate type of COPD patients Klebsiella pneumonie contributed to 
25(22.7%)  followed by  Staphylococcus aureus 12(10.9%).In severe type of COPD 
cases Pseudomonas aeruginosa  contributed to  23(20.9%) followed by Acinetobacter 
baumanii 12(10.9%).This was statistically analysed by Chi square test with a P value 
of <0.001 which was significant.  Nonfermenters   were significantly isolated in 
Severe type. 
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DISTRIBUTION OF   ISOLATES AMONG VARIOUS CATEGORIES OF 
AECOPD FROM RESPIRATORY SAMPLES 
 
 
TABLE 17: DISTRIBUTION OF ETIOLOGICAL ISOLATES AMONG 
VARIOUS CATEGORIES OF AECOPD FROM BLOOD SAMPLES (n=9) 
 
 
Severity Mild Moderate Severe 
Staphylococcus aureus - - 4(44.4 %) 
Klebsiella pneumonia - - 4(44.4%) 
Acinetobacter baumanii - - 1(11.2%) 
 
 All the 3 blood stream isolates were retrieved from severe type of COPD 
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TABLE 18:DISTRIBUTION OF ISOLATES IN STABLE COPD PATIENTS 
(n=50) 
 
Type 
 
Klebsiella pneumoniae Normal flora 
NO % NO % 
MILD 3 6 6 12 
MODERATE 6 12 35 70 
SEVERE - - - - 
 
 Klebsiella  pneumoniae  was the only isolate in stable COPD patients. It  was 
isolated in 12%  from moderate type category  and 6% from  mild type .In remaining 
patients normal flora was isolated. 
TABLE 19: DISTRIBUTION OF KLEBSIELLA PNEUMONIAE ISOLATES 
AMONG AECOPD AND STABLE COPD PATIENTS FROM RESPIRATORY 
SAMPLES IN CULTURE POSITIVE SAMPLES: 
 Klebsiella pneumoniae isolated 
Klebsiella pneumoniae not 
isolated 
AECOPD 37 73 
STABLE COPD 9 0 
 
 Klebsiella pneumoniae isolated was significantly higher in AECOPD patients 
as compare to stable cases.This was analysed statistically by Chisquare test .P value 
was <0.001 which was significant.   
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TABLE 20: ANTIMICROBIAL SUSCEPTIBILITY OF GRAM POSITIVE 
COCCI FROM RESPIRATORY SAMPLES IN AECOPD PATIENTS BY 
KIRBY BAUER DISC DIFFUSION TEST: 
 
Antibiotics 
µg 
Staphylococcus aureus 
n=16 
Streptococcus pneumoniae 
n=7 
No % NO % 
Amikacin(30) 16 100 NA NA 
Penicillin(10 units) 8 50 - - 
Cefoxitin(30) 10 62.5 NA NA 
Ciprofloxacin(5) 12 75 - - 
Chloramphenicol(30) - - 7 100 
Cotrimoxazole(1.25/23.75) 13 81 7 100 
Erythromycin(15) 12 75 7 100 
Ofloxacin(5) - - 7 100 
Oxacillin(1) - - 5 71.4 
Tetracycline(30) 13 81 7 100 
Vancomycin NA  7 100 
 
 NA-These antibiotics are not recommended by CLSI guidelines for that 
particular group of organisms. 
 
 All  Staphylococcus aureus showed 100% sensitivity to Amikacin. All 
Streptococcus pneumoniae isolates from respiratory samples were  100% sensitive to 
Erythromycin, Cotrimoxazole,  Ofloxacin, Tetracycline  and Vancomycin Two of the  
Streptococcus pneumoniae isolates  from the respiratory samples  showed  resistance 
to Oxacillin. 
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TABLE 21:ANTIMICROBIAL SUSCEPTIBILITY OF GRAM NEGATIVE  
COCCI FROM RESPIRATORY SAMPLES IN AECOPD PATIENTS BY 
KIRBY BAUER DISC DIFFUSION TEST: 
 
 
Antibiotics 
µg 
Moraxella catarrhalis 
n=3 
No % 
Amikacin(30) NA NA 
Ampicillin(10) 2 66.6 
Penicillin(10 units) NA NA 
Amoxycillin-Clavulanic 
Acid(20/10) 100 100 
Cefoxitin(30) NA NA 
Ciprofloxacin(5) 3 100 
Cotrimoxazole(1.25/23.75) 2 66.6 
Erythromycin(15) 3 100 
Tetracycline(30) 2 66.6 
 
NA-These antibiotics are not recommended by CLSI guidelines for that particular 
group of organisms. 
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TABLE 22: ANTIMICROBIAL SUSCEPTIBILITY OF 
ENTEROBACTERIACEAE ISOLATES FROM RESPIRATORY SAMPLES IN 
AECOPD PATIENTS BY KIRBY BAUER DISC DIFFUSION TEST: 
 
Antibiotics 
µg 
Klebsiella pneumoniae 
n=37 
Klebsiella oxytoca 
n=8 
NO % NO % 
Amikacin(30) 33 89.1 8 100 
Cefotaxime(30) 14 37.8 5 62.5 
Cefpodoxime 14 37.8 5 62.5 
Cotrimoxazole(1.25/23.75) 21 56.7 5 62.5 
Ciprofloxacin(5) 21 56.7 7 87.5 
Gentamicin(10) 30 81 7 87.5 
Imipenem(10) 34 91.8 7 87.5 
Piperacillin – 
Tazobactam(100/10) 30 81 7 87.5 
Tetracycline(30) 37 100 8 100 
MDR- Multi drug resistance 
 In Klebsiella pneumoniae   resistance to  Cefotaxime, Ciprofloxacin and 
Cotrimoxazole  were shown in 23(62.2%),16(43.3%) and 17(43.3%)  isolates  
respectively. Third generation Cephalosporin  resistance pattern were further 
phenotypically  tested for ESBL production. Multi drug resistance strains 
(Cefotaxime, Ciprofloxacin and Cotrimoxazole  ) was noted in 11(29.7%) of isolates. 
Resistance to Imipenem was noted in 3(8.2%)isolates . 
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 In Klebsiella oxytoca  resistance to Cefotaxime  ,Ciprofloxacin and 
Cotrimoxazole  were shown in  5(37.5%) ,7(12.5%), and 5 (37.5%) isolates 
respectively. Third generation Cephalosporin  resistance pattern were further 
phenotypically  tested for ESBL production. Resistance to Imipenem was noted in 
1(12.5%)isolates .MDR strains was noted in one(12.5%) isolate. 
 
TABLE 23:ANTIMICROBIAL SUSCEPTIBILITY OF KLEBSIELLA 
PNEUMONIAE FROM RESPIRATORY SAMPLES IN STABLE COPD 
PATIENTS BY KIRBY BAUER DISC DIFFUSION TEST: 
 
Antibiotics 
Klebsiella pneumoniae 
n=9 
NO % 
Amikacin(30) 9 100 
Cefotaxime(30) 9 100 
Cotrimoxazole(1.25/23.75) 7 77.8 
Ciprofloxacin(5) 9 100 
Gentamicin(10) 9 100 
Imipenem(10) 9 100 
Piperacillin – 
Tazobactam(100/10) 9 100 
Tetracycline(30) 9 100 
 
 Klebsiella pneumoniae  was the only bacteria isolated from cases of Stable 
COPD patients.2 isolates  (22.2%) were resistant to Cotrimoxazole .All isolates were 
100% susceptible to  Amikacin ,Cefotaxime, Ciprofloxacin,  Gentamicin , Piperacillin 
tazobactam combination. 
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TABLE 24: ANTIMICROBIAL  SUSCEPTIBILITY OF GRAM NEGATIVE 
NON – FERMENTOR ISOLATES FROM RESPIRATORY SAMPLES IN 
AECOPD PATIENTS BY KIRBY BAUER DISC DIFFUSION TEST: 
  
Antibiotics 
Pseudomonas aeruginosa  
n=27 
Acinetobacter baumanii 
n=12 
NO % NO % 
Amikacin 24 88.8 9 75 
Ceftazidime 14 51.3 5 41.7 
Cotrimoxazole NA  8 66.7 
Ciprofloxacin 23 85.1 8 66.7 
Gentamicin 21 77.8 7 58.3 
Imipenem 26 96.3 10 83.3 
Piperacillin – 
Tazobactam 24 88.8 9 75 
 
 
 13 (48.2%) isolates of Pseudomonas aeruginosa  were resistant  to Ceftazidime  
in  and  7(58.3%) Isolates of Acinetobacter baumanii were resistant to Ceftazidime. 
Imipenem resistance was seen in one (3.7%) isolate of  Pseudomonas aeruginosa  and   
two( 16.7%) isolates of  Acinetobacter baumanii.MDR strains were noted in 1(3.7%) 
Pseudomonas aeruginosa  isolate and 3(25%) Acinetobacter baumanii isolate. 
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TABLE 25:ANTIMICROBIAL SUSCEPTIBILITY OF ETIOLOGICAL 
ISOLATES FROM BLOOD  SAMPLES IN AECOPD PATIENTS BY KIRBY 
BAUER DISC DIFFUSION TEST: 
Antibiotics 
µg 
Staphylococcus 
aureus 
n=4 
Klebsiella 
pneumoniae 
n=4 
Acinetobacter 
baumanii 
n=1 
NO NO % % NO % 
Amikacin(30) 4 100 3 75 1 100 
Ampicillin(10) 2 50 - - - - 
Penicillin(10 units) 2 50 - - NA NA 
Cefoxitin(30) 2 50 NA NA NA NA 
Ciprofloxacin(5) 4 100 2 50 1 100 
Ceftazidime(30) - - - - 0  
Cefotaxime(30) - - 1  - - 
Chloramphenicol(30) - - 4 100 1 100 
Cotrimoxazole(1.25/23.75) 4 100 0  1 100 
Erythromycin(15) 4 100 - - - - 
Gentamicin(10) - - 3 75 1 100 
Imipenem(10) NA NA 4 100  100 
Piperacillin – 
Tazobactam(100/10) NA NA 3 75 1 100 
Tetracycline(30) - - 4 100 1 100 
 
 All the Staphylococcus aureus showed 100% sensitivity to Amikacin, 
Ciprofloxacin, Erythromycin,  and  Cotrimoxazole. Among them  two MRSA were 
isolated. Among Klebsiella pneumoniae  all the isolates showed 100% sensitivity to  
Chloramphenicol, Imipenem and Tetracycline. Among them 3 of the isolates were 
ESBL producers. All  Acinetobacter baumanii  isolates showed 100%  
sensitivity to all drugs.  
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TABLE 26: DETERMINATION OF ESBL ISOLATES FROM RESPIRATORY 
AND BLOOD SAMPLES IN AECOPD PATIENTS 
 
S. 
No. Samples Isolates 
Screening 
Test DDST PCDDT 
Positive % No. % No. % 
1. 
Respiratory 
samples 
n=45 
Klebsiella 
pneumoniae 
 
16 
 
35.5 
18 40% 18 40% 
Klebsiella 
oxytoca 2 4.5 
2. 
Blood 
samples 
n=4 
Klebsiella 
pneumoniae 3 75 3 75% 3 75% 
 
DDST – Double disk diffusion synergy test 
 
PCDDT – Phenotypic Confirmatory disk diffusion test 
 
TABLE 27  : DETERMINATION OF IMIPENEM RESISTANT ISOLATES 
FROM RESPIRATORY SAMPLES OF AECOPD  
 
No.of isolates 
n=84 
Imipenem screening –disc 
diffusion method 
Meropenem MIC Macrobroth 
dilution method 
S R MIC value Interpretation 
Klebsiella pneumoniae 
n=37 34 3 64 Resistant 
Klebsiella oxytoca 
n=8 7 1 32 Resistant 
Pseudomonas 
aeruginosa n=27 23 1 64 Resistant 
Acinetobacter baumanii   
n=12 10 2 64 Resistant 
 
 The MIC value of all the seven  isolates  of Gram negative bacilli for 
Meropenem were in resistant range.  
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Table 28: DETERMINATION OF METALLOBETALACTAMASE 
PRODUCTION   BY DDST AMONG AECOPD PATIENTS 
 
Respiratory samples 
 
MBL PRODUCTION 
Positive Negative 
Klebsiella pneumoniae 
n=3 Nil 3 
Klebsiella oxytoca 
n=1 Nil 1 
Pseudomonas aeruginosa 
n=1 Nil 1 
Acinetobacter baumanii   
n=2 Nil 2 
 
DDST :Imipenem- EDTA  double disc synergy test 
None of the isolates were Metallobetalactamase producers. 
 
TABLE 29: DETERMINATION OF Amp C PRODUCTION AMONG    
ISOLATES FROM RESPIRATORY SAMPLES OF AECOPD PATIENTS 
 
Isolate 
 
Screening test 
positive 
AmpC disc confirmatory 
test positive 
Klebsiella pneumoniae 
n=3 Nil - 
Klebsiella oxytoca 
n=1 Nil - 
Pseudomonas aeruginosa 
n=3 Nil - 
Acinetobacter baumanii 
n=2 1 1 
 
 According to AmpC production definition Only one isolate among 12       
Acinetobacter baumanii  isolates  from endotracheal aspirate   were AmpC 
producer(8.%). 
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TABLE 30: DETERMINATION OF CARBAPENAMASE PRODUCTION 
AMONG IMIPENEM RESISTANT ISOLATES FROM RESPIRATORY 
ISOLATES IN AECOPD PATIENTS BY MODIFIED  
HODGE TEST(MHT)  n=7 
Isolates NO Positive % 
Klebsiella 
pneumoniae 3 2 28.5 
Klebsiella oxytoca 1 -  
Pseudomonas 
aeruginosa 1 -  
Acinetobacter 
baumanii 2 1 14.3 
 
 Imipenem resistance was taken as indicator for Carbapenemase production. 
Among 7 Imipenem resistant isolates 2(28.5%) Klebsiella pneumonia isolates and 1 
(14.3%)  Acinetobacter baumanii  isolate  were Carbapenemase producing organism 
which was comfirmed by MHT. 
Table 31: DETERMINATION OF METHICILLIN RESISTANCE AND 
VANCOMYCIN MIC OF STAPHYLOCOCCUS AUREUS BY MACROBROTH 
DILUTION METHOD ISOLATES FROM RESPIRATORY SAMPLES OF 
AECOPD PATIENTS(N=16) 
 
Cefoxitin screening –disc diffusion 
method MIC of 
Vancomycin Result 
Sensitive Resistant % 
10 6 37.5 ≤2µg/ml Sensitive 
 
 Among 16 isolates 6(37.5%) isolates were Methicillin resistant.  All  MRSA  
isolates had  MIC ≤2µg/ml for Vancomycin and therefore considered  sensitive. 
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Table 32 :DETERMINATION OF DRUG RESISTANT STREPTOCOCCUS  
PNEUMONIAE  ISOLATES FROM RESPIRATORY SAMPLES OF AECOPD 
(n=7) 
 
Oxacillin screening –disc 
diffusion method 
Penicillin MIC by E test 
 
S R % MIC value Interpretation 
5 2 28.5 
0.094µg/ml
0.094µg/ml
Intermediate resistance 
Intermediate resistance 
 
 The MIC value of all the two   isolates   of  Streptococcus  pneumoniae  were 
in intermediate range. 
 
TABLE 33: DISTRIBUTION  OF  RESISTANT ISOLATES  AS PER AECOPD 
SEVERITY IN RESPIRATORY SAMPLES 
 
Severity MRSA n=6 
Pencillin 
resistant 
Streptococcus 
pneumoniae 
n=7 
E
SB
L 
n=
18
 
Im
ip
en
em
 
R
es
ist
an
t 
n=
4 
M
H
T
 
n=
2 
A
m
pC
 
Im
ip
en
em
 
re
sis
ta
nt
 
n=
3 
M
H
T
 
n=
1  
A
m
pC
 
n=
1 
Enterobacteriaceae 
Non- 
Enterobacteriaceae 
n=39 
Mild  -  
- 
 - Nil Nil - Nil - 
Mod 4 66.7% 
- 
 
12 
66.7% - - - - - - 
Severe 2 33.3% 
2 
100% 
6 
33.3% 
4 
100%
2 
100% - 
3 
100% 
 
1 
100% 
1 
100%
 
 
   
MHT- Modified Hodge test 
MRSA- Methicillin resistant Staphylococcus aureus 
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ESBL-Extended spectrum betalactamase 
 
 This was analysed statistically by Chisquare test which showed a P value of 
<0.001 . It was significant. So Presence of MRSA and ESBL isolates were 
significantly higher in Moderate AECOPD  patients (66.6%, 66.6% , respectively) 
than in severe group (33.3%,33.3%). Penicillin   resistant   Streptococcus  
pneumoniae, Imipenem resistance, Carbapenamase  producing isolates(Modified 
hodge test positive),Amp C producing strain were significantly higher   in severe 
AECOPD patients (100%). 
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DISCUSSION 
 
 This Cross sectional study was conducted at the Institute of Microbiology, 
Madras Medical  College in association with Departments  of InternalMedicine, 
Thoracic Medicine, Intensive Medical Care Unit at the Rajiv Gandhi Government 
General Hospital, Chennai. The  study population consisted of 150 patients with 
AECOPD and 50 patients with Stable COPD .The Stable COPD patients were 
included as a control population to compare the pattern of microorganisms isolated. 
Patients were  selected according to GOLD(14) criteria .  
 
The study population included in the AECOPD category were in the age group 
of  40-90 years .The majority of AECOPD patients were in the age group of 61-70 
years (30%) (Table 1).In the Stable COPD category, 42% patients were in the age 
group of 61-70 years (Table 2).This can be explained by the fact that COPD  has the 
highest prevalence after  fifth and sixth decade of life . As age advances ,the 
physiological decrease in lung function is accentuated by the cumulative damage done 
by smoking and other co morbid conditions.(67) This study observation corresponds to 
studies of Alladi Mohan et al, N Arora et al and Pallavi Torka et al. (68-70) 
 
 There was a predominance of males  over females  in both  AECOPD (82.7% 
and 17.3% )  and in stable COPD (84% and 16%) patients(Table 1,Table 2). This can 
be explained by the fact that men have pronounced smoking habits and are exposed 
more to outside environment as compared to females. This was  similar to the study 
done by Chawla k et al. (75) 
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 Smoking leads to decreased mucociliary clearance and innate immunity 
thereby leading to increased bacterial colonization that can give rise to increased 
airway inflammation and thus exacerbation.(71)In the present study smoking was 
associated with AECOPD in 81.3% of cases and 84% in Stable COPD cases(Table 3) 
followed by Biogas inhalation (13.3%) in AECOPD and 14% in stable COPD which 
was associated with female patients. This was similar to a study done by Jindal et al.  
who stated that smoking is associated with COPD in 80-85% of cases.(67) A  study by 
Salvi et al. also states  that   indoor air pollution from burning biomass fuels is 
associated with an increased risk of COPD in developing countries.(105)Occupation as 
a risk factor of COPD was found only in 0.6% of patients in AECOPD and 2% in 
stable COPD.(Table 4). A study done by Piera Boschetto et al states that  
approximately 15% of COPD is   occupation related(103) which is quite high as 
compared to this study. 
 
 Most common clinical   diagnosis in both AECOPD and stable COPD patients  
was Chronic Bronchitis in (95.3% and 94%) respectively(Table 5). American Lung 
Association Lung Disease 2013   has estimated a higher prevalence of chronic 
bronchitis as compared to emphysema.(106) 
 
 The study group were selected based on Spirometric studies (GOLD 
criteria)(14).As per this criteria the most common type was moderate type (57.3%) 
followed  by severe type (40%) in AECOPD patients. Karin et al. reported the severity 
of COPD as 47% ( severe)and 32% (moderate). (81)Among Stable COPD patients most 
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common type was moderate type (82%) followed by Mild type (18%).No Severe type 
of COPD were detected in stable patients.(Table 9) 
 
 The AECOPD was further categorised as per Anthosien criteria(15). 
 
 Anthosien criteria is based on 3 cardinal symptoms -increased breathlessness, 
Increased volume of sputum and Increased purulence of sputum among which 
increase sputum purulence was more important for bacterial isolation.(15) 
 
 According to these criteria Increased level of breathlessness was the 
commonest symptom in AECOPD (100%).Next most common symptom was 
increased in sputum volume (80%), and sputum purulence (72.6%)(Table 6). This is 
in accordance with the study of N. Arora et al where 100% of patients had increase in 
sputum volume and 98.28% had various grades of dyspnoea. (68)  
 
 According to this criteria   Type 1 exacerbation was the commonest (72.6%) 
type of AECOPD with all three cardinal  symptoms   followed by  Type3 exacerbation 
(20%). (Table 7).  
 
 Complications were observed in  24% patients among AECOPD patients 
among which Respiratory failure  was the most common complication(8%) followed 
by Corpulmonale (7.3%) and Bacteremia (6%) (Table 8) .These observations were 
corresponding to a study done by Alladi mohan et al. who reported   Cor pulmonale in 
10% and Type I Respiratory failure in  8% of patients.(74)Stable COPD study group 
was not associated   with   any  complication . 
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  The most common sample collected and processed from patients with 
AECOPD was Sputum (79.3%) followed by Endotracheal aspirate (8%). In addition 
,Bronchial wash 6.6% and  Induced sputum 6%  were collected and processed . 
(Table10) 
 
 Out of 150 samples , 70.6%   showed culture positivity and 29.4% (Table 10) 
showed culture negativity. Bronchial wash and Endotracheal aspirate had the highest 
culture positivity rate of 100% and 91.6% respectively followed by sputum( 
64.7%).(Table 10). Alamoudi OS et al. obtained growth in 69.8% of sputum samples 
which is corresponding with our study. (76) A similar observation was  made by Arora 
et al. in which culture was positive in 72% cases among all respiratory samples(68). 
 
 The correlation of Sputum purulence with culture positivity   was found to be 
statistically significant with a P value <0.001( Table 13). This correlates with the  
study done by Stockley RA et al., Soler et al and  Chawla K et al. who reported a 
culture positivity among 84% ,84% and 56% respectively from purulent sputum 
samples  from AECOPD patients. This proves that purulent sputum is the surrogate 
marker of bacterial infection as they yield  positive bacterial cultures as compared to 
non purulent sputum.(72,73)  
 
 A Single organism was identified in 96.2% while  poly bacterial growth was  
observed in 3.8% (Table 11). 
 
 Gerard rakesh  et al. in their study on bacterial agents in AECOPD revealed  
37% of  monobacterial isolates and 5% of  polybacterial isolates.(91) 
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 In a study done  by Chawla k et al.a single organism was isolated in most of the 
samples 92.85%  and growth of two organisms was isolated in 7.14% cases. This was 
corresponding to the present   study. (75) 
 
 The commonest organism in the respiratory samples in AECOPD patients were 
Gram negative   bacteria (77.4%) as compared to Gram positive bacteria 
(22.5%)(Table 12). Among Gram negative organisms, Klebsiella pneumoniae 33.3% 
was the most commonly and significantly isolated organism(P<0.001) followed by 
Pseudomonas aeruginosa 23.5% ,  Klebsiella oxytoca 6.8%, Acinetobacter baumanii 
10.7% and Moraxella catarrhalis 2.9% (Table14).Among Gram positive organisms, 
Staphylococcus aureus was most commonly isolated in 15.6% cases and 
Streptococcus pneumoniae  in 6.8% of cases.  
 
 This is similar to the findings of Pradhan K .C et al who reported Klebsiella 
pneumoniae as the predominant organism (40% )followed by Staphylococcus aureus 
(26%) and Pseudomonas aeruginosa (13%). (82,83) 
 
 In a study done by Chawla K et al. Pseudomonas aeruginosa was the 
predominant isolate (25.92%) amongst the hospitalized patients followed by 
Streptococcus pneumoniae and Acinetobacter spp (18.51% each), Klebsiella spp. and 
Moraxella  catarrhalis (14.80% each).(75) 
 
  Madhavi et al. observed that the commonest isolate was Klebsiella 
pneumoniae   (59%), followed by Pseudomonas aeruginosa 15%, Staphylococcus 
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aureus 13.6%, Streptococcus pneumoniae 6.8% among AECOPD patients.(84)This was 
also corresponding to this   study observation. 
              
 In a study done  by Karien H. et.al. at University Hospital Maastricht in  
Netherlands most frequently isolated microorganisms were Haemophilus influenzae 
(45%) and Streptococcus pneumoniae (27%). Other pathogens isolated were 
Pseudomonas aeruginosa (15%), Moraxella catarrhalis (6%) and Klebsiella 
pneumoniae (5%). (81) 
 
 A study done by Eller jorg et al. stated that the predominant organism causing 
AECOPD was Streptococcus pneumoniae  , non typable Haemophilus influenzae and 
Moraxella  catarrhalis .(78) 
 
 Organisms isolated in western countries are different from our country. In 
contrast to Western literature , review of Indian literature shows no isolates of  
Haemophilus influenzae  in AECOPD patients. This possible change in etiologic 
pattern may be due to advent of newer antibiotics with their indiscriminate usage, 
local practices of antibiotic usage or this might be due to the reason that   the 
frequency of infection resulting in AECOPD by various microorganisms varies from 
one geographical area to another as our country has a wide climatic variation, small 
houses and high levels of indoor pollution. (85) 
 
 On analysis of the distribution of etiologic agents among various category of 
AECOPD it was found that in moderate type of COPD patients Klebsiella pneumonia 
contributed to 22.7% followed by Staphylococcus aureus 10.9%.In severe type 
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Pseudomonas aeruginosa  contributed to 20.9% followed by Acinetobacter baumanii   
10.9%(Table 16). Thus Non fermenters  were significantly isolated in Severe type and  
Klebsiella pneumoniae  from Moderate type with a significant P value of <0.001. 
 
 The present study observations  corresponds to the  study done by Eller jorg et 
al. which states that prevalence of Pseudomonas and Acinetobacter   increases in 
patients with declining lung function(78).Similarly a study done by N.Roche et al. in 
2007 reports  that 8.5% of  Pseudomonas sp were  from   patients with severe 
COPD(79). 
 
 Niederman micheal s.et al have mentioned in their   study   that   Gram 
negative bacteria was the commonest bacteria isolated (80). This study also corresponds 
with our findings. 
 
 Mixed infection among AECOPD patients was found in 3.8% of culture 
positive cases which was observed in three   endotracheal aspirate and a single sputum 
sample.(Table 11).This polymicrobial infection was seen with  Klebsiella pneumoniae 
and Pseudomonas aeruginosa followed by Klebsiella oxytoca and  Acinetobacter  
baumanii. Gerard Rakesh  et al. reported mixed infection in  two cases of  Klebsiella 
pneumoniae and Pseudomonas aeruginosa  and 3 cases of Klebsiella pneumoniae and 
Staphylococcus aureus which was similar to our findings (91) . 
 
 In stable COPD patients, culture positivity was 18% (Table 19). Klebsiella  
pneumoniae   was the only potential pathogen  isolated  in 18% of these cases. In all 
other patients normal flora   82%   were isolated. . Klebsiella  pneumoniae  was 
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isolated  from 12% of moderate type  and 6% of mild type .(Table 18) This was 
similar to study done by Mc Hardy et al. and Zalacain et al. who stated in their study 
that approximately 20–30% of patients with COPD have positive sputum bacterial 
cultures when clinically stable, and the presence of bacteria has been shown to be 
related to the degree of airflow obstruction and current cigarette smoking status(86,87). 
 
 A  study done by Monso et al. and  Rosell et al.   studied   stable and acute 
exacerbations among COPD patients and observed that lower airway  bacterial 
colonizers with Stable COPD were similar to those bacteria detected during 
exacerbations(86,87). Klebsiella pneumoniae isolated was significantly higher in 
AECOPD patients as compared to stable cases(P<0.001)(Table 19).So in our study the  
Klebsiella pneumoniae  isolated from Stable COPD patients could be  airway 
colonizers as the isolation rate among AECOPD were high .The absence of symptoms 
in Stable COPD  patients with lower airways colonized by potentially pathogenic 
organisms might be related to the bacterial load. Bacterial colonization might be due 
to  failure to sterilise bronchial secretions after treatment of an episode of exacerbation   
which might   lead to growth of microorganisms newer to lower airways without the 
symptoms of exacerbation(88,89,90). 
  
 The antibiogram performed  for various isolates were analysed .The 
commonest Gram negative bacilli isolated  from respiratory samples of AECOPD 
patients was   Klebsiella pneumoniae   showed Multi drug resistance (MDR) in  
29.7%  of patients .Resistance  due to Cefotaxime Ciprofloxacin , and  Cotrimoxazole  
in 62.2% , 43.3% and  43.3% respectively.   Resistance to Imipenem was noted in 
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8.2% of  isolates .(Table 22) Thus Klebsiella pneumoniae   showed a significant level 
of  resistance to third generation Cephalsporins and β lactamase inhibitor 
combinations . The prevalence of Carbapenemase production in   Klebsiella 
pneumoniae   was 28.5%. (Table :30) 
 
 This implies that Klebsiella pneumoniae was one of the important drug 
resistant pathogens isolated   among  AECOPD patients. The   resistance to 
Cefotaxime  ,Cotrimazole, Ciprofloxacin , (62.2% ,43.3%,and 43.3% respectively) 
and Imipenem 8.2% was higher in isolates from AECOPD patients than in Stable 
COPD patients. [Table:22,23] 
 
 Studies performed by Madhavi et al  observed  resistance of Klebsiella 
pneumoniae to Cefotaxime 62% ,Ciprofloxacin 42% and  Cotrimoxazole 96% which 
was almost similar to our findings(84). 
 
 The other member of family Enterobacteriaceae isolated  was  Klebsiella 
oxytoca . Resistance to Cefotaxime  37.5%,Ciprofloxacin 12.5% and Cotrimoxazole  
37.5%  was also noted among  Klebsiella oxytoca isolated with a MDR frequency of 
12.5%. (Table 22) 
 
 The frequency of ESBL producers (Table :26) among Enterobacteriaceae was 
40%  among  which 35.5% were Klebsiella pneumoniae isolates  and  4.5% were   
Klebsiella oxytoca isolates. In a study done by Gerard rakesh et al.it was observed that 
23.81% of Klebsiella pneumoniae were ESBL producers  (91).  Study done by SMART 
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2007 stated  ESBL rates in India for  Klebsiella pneumoniae, and Klebsiella oxytoca 
were, 69.4%, and 100%, respectively which was  higher as compared to this study(102). 
 
 The most common non-fermenter   isolated from the respiratory samples of 
AECOPD patients   was  Pseudomonas aeruginosa (Table:24),which showed 48.2% 
resistance   to Ceftazidime. Pseudomonas aeruginosa   had 3.7% Imipenem resistance. 
MDR strains were noted in 3.7% cases. Thus it showed a siginificant level of 
resistance to third generation Cephalosporin. This implies that Pseudomonas 
aeruginosa was   also   one of the important drug resistant pathogen isolated from 
cases of AECOPD. 
 
 This resistance pattern was similar to a study done by Chawla et al. who stated 
60% resistance of   Pseudomonas aeruginosa to third generation Cephalosporins(75). 
 
 This resistance pattern was similar to the studies done by Fluit et al. and Jones 
et al. who found that  Pseudomonas aeruginosa  had high level resistance to third   
generation Cephalosporins  and  also found that Piperacillin /tazobactam to be as 
potent as Amikacin, with resistance rates as low as 10–17%(93,94). 
 
 Non fermenter Acinetobacter baumanii isolates from AECOPD   cases showed   
resistance to Ceftazidime 58.3% ,Ciprofloxacin 33.3% and Cotrimoxazole 33.3%. 
MDR(Multi drug resistant) strains were noted in  25% of Acinetobacter baumanii 
isolates.(Table 24)  Thus it showed a significant level of resistance to third generation 
Cephalosporin. It showed   16.7% resistance to   Imipenem .The proportion of  
Acinetobacter baumanii   isolate producing  Carbapenemase  production   was 14.3%  
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and 8% were Amp C producers (Table 29 ,30).This implies that Acinetobacter 
baumanii  was also  one of the important drug resistant pathogens isolated from cases 
of AECOPD.  
 
 This was in contrast to the study conducted in Asia pacific region by Wang 
huei Sheng  et al. in 2013,where 15.3% of Acinetobacter baumanii  isolates from 
lower respiratory tract infections were Amp C producers. 
 
 Thus in the present study ,among the mechanisms for developing resistance to 
third generation Cephalosporins,   ESBL production was more commonly identified 
than Carbapenemase and   Amp C production.No MBL producers were identified 
among Gram negative bacilli in the study. 
 
 Gram negative cocci (Moraxella catarrhalis) isolates from the respiratory 
samples of AECOPD patients showed 100% sensitivity to Ciprofloxacin, 
Erythromycin and Amoxycillin- Clavulanic acid combination. 
 
 Whereas in a study done by Karien et al have stated 2% of their Moraxella 
isolates were β lactamase producers.(8)  
 
 The most common gram positive isolates from respiratory samples in 
AECOPD patients in our study was Staphylococcus aureus   (Table 14). The 
proportion of Staphylococcus aureus   with  Methicillin   resistance  was 37.5% . 
(Table 31). A study conducted by INSAR group stated that the prevalence of MRSA 
in India is about 40%(97). This study statement correlates with this present study. In a 
study done by Gerard Rakesh et al. among AECOPD patients, the frequency of 
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Methicillin - Resistant Staphylococcus aureus was reported as 11.90% which was 
lesser as compared to our study observation. Chawla K et al .in their study observed 
that   50%   of Staphylococcus aureus isolates were MRSA (75).All   the MRSA 
isolates in our study was sensitive to Vancomycin. 
 
 All Streptococcus pneumoniae isolates from respiratory samples   were   100% 
sensitive to Erythromycin,  Cotrimoxazole,  Ofloxacin, Tetracycline  and 
Vancomycin. Two of   the  isolates showed  resistance to Oxacillin by disc diffusion 
.(Table 20) The MIC to Penicillin which was determined by E  strip showed 
intermediate resistance in  28.5%.(Table 32) .Thus there was a disparity of 
susceptibility between disc diffusion and MIC determination. 
 
 A study done by Goyal et al. in North India stated that 30 Streptococcus  
pneumoniae isolates were resistant to penicillin by Oxacillin disc diffusion method. 
Determination of MIC of these strains by broth dilution and E test revealed   that   26 
of isolates had  intermediate resistance and only four isolates had complete resistance 
to penicillin .(99)This study also showed  disparity of susceptibility between disc 
diffusion and MIC determination  which was similar to this  study. 
 
 Investigations of outbreaks by Center for Disease Control   have revealed that 
Pneumococcal isolates resistant  to penicillin in some areas of the United States is as 
high as  30%(98). 
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 A   high   prevalence of Intermediate resistance to Penicillin (69.9%  )among 
AECOPD patients has been noted by Fanny et al. which was quite higher as compared 
to our findings(92). 
  
 Study conducted by Iain B Gosbell et al stated   that the prevalence of PRSP 
(Penicillin Resistant Streptococcus pneumoniae) was about 20%(100) . Emilio Perez –
trallero et al. in their study stated that   Streptococcus pneumoniae isolates obtained 
from AECOPD patients were more resistant to the antimicrobial agents generally used 
in the treatment of pneumococcal infections than those isolated from patients with 
pneumonia. This result was expected, as patients with COPD usually receive 
antimicrobial treatments because of frequent acute bacterial exacerbations and the 
association between antibiotic consumption and antimicrobial resistance has been 
demonstrated widely  (101). 
 
 Though MDR pathogens were present in both moderate and severe type of 
COPD the frequency of MRSA and ESBL isolates were higher in Moderate AECOPD  
patients (66.7%, 66.7% , respectively) than in severe group(33.3%,33.3%). Penicillin  
resistant  Streptococcus  pneumoniae  , Imipenem resistance, Carbapenamase  
producing isolates  and  Amp C producing strains were significantly higher in severe 
AECOPD patients than in moderate type ( P value <0.001)(Table :34). MDR 
pathogens were present both in moderate and severe type of COPD. 
 
 Bacteremia among AECOPD patients was  observed in 6% cases. (Table 10).  
In a study done by Laura solano et al., Spain ,bacteremia was noted  in 10% of 
AECOPD patients admitted in Intensive care unit(77) . 
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 The commonest pathogens isolated from blood were   Staphylococcus aureus 
(44.4%) and  Klebsiella pneumoniae (44.4%) followed by  Acinetobacter baumanii 
(11.1%). Among Staphylococcus aureus 50% were MRSA. In Klebsiella  pneumoniae   
ESBL production was observed in 75% cases. All  Acinetobacter baumanii  isolates 
showed 100% sensitivity  to all drugs.  (Table:25). No MRSA and ESBL producing 
blood stream isolates was observed in the study done by Laura Solano et. al.(77) 
 
 H. influenzae was not isolated in the present study. This could  be  due to  prior 
antibiotic use or seasonal variations in causation. This is in concordance with previous 
studies conducted by   Wilson et al., in 1999 and Allegra et al in 1996(85,110). 
 
 No Fungal pathogens were isolated in this study which was corresponding to 
all other Indian studies (8,39). 
  
 
 
 
 
 
 
SUMMARY 
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SUMMARY 
 
 This study conducted at the Institute of Microbiology, Madras Medical College 
and RGGGH in analyzing and comparing the etiologic agents of AECOPD and Stable 
COPD patients revealed the following findings. 
 
 The majority number of AECOPD and Stable COPD   patients were in 61-70 
years age group. 
 There was a predominance of  males  over females  in both  AECOPD (82.7% 
and 17.3% )  and in stable COPD (84% and 16%) patients.  
 Smoking was associated with AECOPD in76.6% of cases and 82% among 
COPD patients .Biogas inhalation was associated with AECOPD in 13.3% of 
cases and 14% among COPD cases. Smoking was the commonest risk factor in 
both the study groups. 
 Chronic bronchitis was the most common condition in both stable (95.3%) and 
acute exacerbation(94%) of COPD. 
 According to Anthosien criteria increased level of breathlessness was the 
commonest symptom in AECOPD (100%).Next most common symptom was 
increased in sputum volume(80%),and sputum purulence(72.6%) 
 As per Anthosien  criteria  Type 1 exacerbation was the commonest type 
(72.6% ) followed by  Type3 exacerbation(20%). 
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 Complications were observed in  (24%) patients among AECOPD patients 
among which Respiratory failure (8%) was the most common complication 
followed by Corpulmonale 11 (7.3%) and Bacteremia 9(6%).Stable COPD 
study group was not associated with any  complication . 
 Among AECOPD patients the most common type was Moderate type (57.3%)  
followed  by  Severe type (40%).Among Stable COPD patients the most 
common type was moderate type (82%) followed by Mild type (18%). 
 The commonest sample for culture was Sputum sample (79.3%) followed by 
Endotracheal aspirate (8%). 
 Bronchial wash   and   Endotracheal aspirate had the highest culture positivity 
rate of 100% and 91.6% respectively followed by sputum (64.7%).  
 Among the respiratory samples  70.6%   showed culture positivity. 
 Pure Monobacterial type of isolates was   96.2%. Poly bacterial type of isolates 
were 3.8%. 
 Among Gram positive organisms isolated from respiratory samples 
Staphylococcus aureus was the most commonly isolated  in 15.6% cases and 
Streptococcus pneumoniae in 6.8% of patients.Among Gram negative 
organisms Klebsiella pneumoniae was the most commonly isolated organism 
(33.3%)  followed by  Pseudomonas aeruginosa  (23.5%), Klebsiella oxytoca 
(6.8%), Acinetobacter baumanii (10.7%) and Moraxella catarrhalis (2.9%) . 
 In moderate type of COPD patients Klebsiella pneumoniae  contributed to 
22.7% followed by Staphylococcus aureus 10.9% of infections.In severe type 
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Pseudomonas aeruginosa  contributed to 20.9% followed by Acinetobacter 
baumanii   (10.9%). 
 Non fermenters  were significantly isolated in Severe type as compared to the 
moderate type with a significant P value of <0.001. 
 All Staphylococcus aureus isolates from AECOPD  patients were 100% 
sensitive to Vancomycin.  
 The frequency  of MRSA in AECOPD patients was 37.5%. 
 The frequency  of Intermediate resistance to Penicillin in Streptococcus 
pneumoniae (PRSP) was  28.5%. 
 The Isolation rate  of ESBL producers were  40%  among  which 35.5% were 
Klebsiella pneumoniae isolates  and  4.5%  were Klebsiella oxytoca isolates. 
 The prevalence of Carbapenemase production in   Klebsiella pneumoniae   was 
28.5% and for Acinetobacter baumanii  was 14.3% . 
 The prevalence of Amp C producers  in  Acinetobacter baumanii  was 8% .  
 Presence of MRSA and ESBL isolates were higher in Moderate AECOPD  
patients (66.6%, 66.6% , r espectively) than in severe group(33.3%,33.3%).  
 Penicillin   resistant  Streptococcus  pneumoniae  , Imipenem resistance, 
Carbapenamase  producing isolates, Amp C producing strain were all more 
common  in severe AECOPD patients (100%) than in moderate type which 
were statistically significant. 
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 The Polybacterial  infection was found in three endotracheal aspirates and a 
single sputum sample among which the most common combined isolates were 
Klebsiella pneumoniae and Pseudomonas aeruginosa. 
 In stable COPD patients Klebsiella  pneumoniae   was the only potential 
pathogen  isolated  in 18% of patients. 
 6% of the patients with AECOPD had Bacteremia. 
 Bacteremia was observed in severe type of COPD only. 
 No Fungal pathogens were isolated in this study . 
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CONCLUSION 
 Exacerbations punctuate the clinical course of COPD in many patients. 
Exacerbations, mostly of an infectious etiology, are a frequent cause of morbidity in 
COPD patients .So this study has been taken to analyse the bacterial and fungal profile 
with their sensitivity pattern. 
             In our study Bacterial infections are the most common reason for 
exacerbations, among which   Klebsiella  pneumoniae and Pseudomonas aeruginosa  
were the commonest. Purulent sputum sample is a good and easy to obtain, non 
invasive sample that   provides preliminary idea about the pathogens , thereby helping 
in selecting antibiotics for empirical antibiotic therapy as the culture positivity is high 
in these samples. Quantification of sputum sample is necessary to obtain   the actual 
pathogen. As 6% of the patients showed  Bacteremia  it is necessary to perform blood 
culture in patients associated with fever. Few cases of  polymicrobial infections was 
observed .  
                 As Klebsiella pneumoniae  were isolated from Stable COPD patients as 
well ,   these organisms could be  airway colonizers as the isolation rate among 
AECOPD were also high  .The absence of symptoms in Stable COPD  patients with 
lower airways colonized by potentially pathogenic organisms might be related to 
lower bacterial load. 
 
 Antibiotics are important in treatment of AECOPD. Present study and few 
previous Indian studies have shown that bacterial pathogens responsible   for 
AECOPD is different in our country from that of western countries and so is their 
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sensitivity pattern . Pseudomonas aeruginosa  and  Acinetobacter baumanii  were 
significantly isolated in Severe type and Klebsiella  pneumoniae  from Moderate type . 
ESBL ,  Carbapenemase , AmpC, MRSA producers and Penicillin resistant 
Streptococcus pneumoniae strains were significantly isolated in Severe type of 
AECOPD patients in our study which   increased the morbidity. MDR pathogens were 
present both in moderate and severe type of COPD. There was a disparity of 
susceptibility between disc diffusion and MIC determination in Streptococcus 
pneumoniae for Penicillin so it is always necessary to perfom MIC before reporting 
sensitivity pattern. 
 The choice of antibiotics depends on the local antibiotic policy and the pattern 
of local pathogens. Hence Periodic isolation and identification of resistant status of 
pathogens responsible for AECOPD will help us to formulate appropriate treatment 
protocol   which will be of immense use in reducing mortality and morbidity besides 
reducing the volume of antibiotics and development of resistance to antibiotics. 
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APPENDIX-I 
ABBREVIATIONS 
 
AECOPD  Acute exacerbation of Chronic obstructive pulmonary Disease 
ATCC           American Type Culture Collections 
CLSI                     Clinical & Laboratory Standards Institute 
COPD                    Chronic obstructive pulmonary   Disease 
DDST           Double Disk Diffusion Synergy Test 
ESBL           Extended Spectrum Beta Lactamases 
FEV1                      Forced expiratory volume  
FVC                        Forced vital capacity 
GNB                     Gram – Negative Bacilli 
GPC           Gram – Positive Cocci 
CAMHA                Cation adjusted  Muller Hinton Agar 
MBL           Metallo ß-Lactamases 
MIC           Minimum Inhibitory Concentration 
MRSA                   Methicillin Resistant Staphylococcus aureus 
MSSA          Methicillin Sensitive Staphylococcus aureus 
PCDDT          Phenotypic Confirmatory Disk Diffusion Test 
RPMI 1640          Rose Parker Memorial Institute 1640 
S.aureus         Staphylococcus aureus 
MDR                     Multi Drug Resistance 
 
 
 
APPENDIX-II 
 
A. STAINS AND REAGENTS 
I.  Gram staining 
 Methyl violet (2%)   l0g Methyl violet in 100ml  
                                                      absolute alcohol in 1 litre of 
               distilled water (primary stain) 
 
 Grams Iodine   l0g Iodine in 20g KI(fixative) 
  
 Acetone    Decolourising agent 
 
 Carbol fuchsin 1%   Secondary stain 
 
 
II. Lactophenol cotton blue stain 
Lactic acid     20 ml 
Phenol     20ml 
Cotton blue (dye)    0.5g 
Glycerol     40ml 
Distilled water    20ml 
 
III. 10% KOH 
Potassium hydroxide  10g 
Glycerol    10ml 
Distilled water             80ml 
 
IV  Acid fast stain 
 
Basic fuchsin powder                     5g 
Phenol (crystalline)                        25g 
Alcohol(95% or 100% ethanol)     50ml 
Distilled water                                500ml 
 
20% Sulphuric acid 
Conc Sulphuric acid(98%)             250ml 
Distilled water                                1L 
 
Methylene  blue counterstain 
1% Methylene blue 
  
A. BROTH  USED 
 
1. Brain Heart Infusion broth: 
Ingredients                                         Gms / Litre 
Peptic digest of animal tissue             10.000 
Calf brain, infusion (solids)                12.500 
Beef heart, infusion (solids)                5.000 
     Dextrose                                            2.000 
Sodium chloride                                 5.000 
Disodium phosphate                           2.500 
Final pH (at 25°C)                             7.4±0.2 
 
37 grams of media is suspended in 1000 ml distilled water. Dispense into bottles or 
tubes and sterilized by autoclaving at 15 lbs pressure (121°C) for 15 minutes. 
 
2. Cation adjusted Mueller Hinton Broth: 
 
Ingredients                                      Gms / Litre 
Beef extract                                    3.000 
Casein acid hydrolysate                 17.500 
Starch                                             1.500 
Calcium                                          20-25 mg/l 
Magnesium                                     10-12.5 mg/l 
Final pH (at 25°C)                          7.3±0.2 
 
22 grams of media is suspended in 1000 ml of distilled water. Dissolve the medium 
completely. Dispense and sterilize by autoclaving at 115-121°C for 10 minutes. DO 
NOT OVERHEAT. 
 
3. Trypticase soy broth 
 
Ingredients                                           Gms / Litre 
Pancreatic digest of casein                       17.000 
Papaic digest of soyabean meal                 3.000 
Sodium chloride                                         5.000 
Dextrose                                                     2.500 
Dibasic potassium phosphate                    2.500 
Final pH ( at 25°C)                                    7.3±0.2 
               
30 grams of media is suspended in 1000 ml of distilled water. Dissolve the                  
medium completely. Dispense and sterilize by autoclaving at 115-121°C for 10     
minutes. DO NOT OVERHEAT 
 
  
B. MEDIA USED 
1. Mac Conkey agar 
Peptone     20g 
S odium taurocholate   5 g 
Distilled Water    1 ltr 
Agar                20 g 
2% neutral red in 50% ethanol        3.5ml 
10% lactose solution    l00ml 
 
Dissolve peptone and taurocholate in water by heating. Add agar and dissolve it in 
steamer. Adjust pH to 7.5. Add lactose and neutral red shake well and mix.Heat in 
free steam (100°C) for 1 hour, then autoclave at 115°C for 15 minutes. 
2. Blood agar (5% sheep blood agar) 
 Peptone     l0g 
 NaCl      5g 
 Distilled water    1Ltr 
 Agar       l0g 
Dissolve ingredients in distilled water by boiling, and add 5% sheep blood(sterile) at 
55°C adjust pH to 7.4. 
3. Chocolate agar 
 Sterile defibrinated blood   10 ml 
 Nutrient Agar (melted)   100 ml 
When the temperature was about 75°C, sterile blood was added with constant 
agitation. After addition of blood, kept in water bath and heating was continued till 
the blood changed to chocolate colour. Cooled to about 50° C and poured about 
15ml into petri dishes with sterile precaution. 
4. Sabouraud's dextrose agar 
 Dextrose     40 g 
 Peptone     10g 
 Agar      20g 
 Distilled water    1000ml 
 pH = 5.5 
  
 
5. Mueller- Hinton Agar 
Beef infusion  300ml 
Caesein hydrolysate  17.5g 
Starch  1.5g 
Agar  lOg 
Distilled water  lltr 
pH = 7.4 
 
Sterilise by autoclaving at 121°C for 20 mins 
 
IDENTIFICATION 
1. Oxidase Reagent 
 Tetra methyl p-phenylene diamine dihyrochloride- 1% aqueous solution. 
 
2. Catalase 
3% hydrogen peroxide 
 
3.Indole test 
Kovac's reagent 
Amyl or isoamyl alcohol                                 150ml  
Para dimethyl amino benzaldehyde                 lOg  
Concentrated hydrochloric acid                       50ml 
 
Dissolve the aldehyde in the alcohol and slowly add the acid. Prepare in small quantities and 
store in the refrigerator. Shake gently before use. 
 
4.Christensen's Urease test medium 
 Peptone lg 
 Sodium chloride 5g 
 Dipotassium hydrogen phosphate 2g 
 Phenol red 6ml 
 Agar 20g 
 Distilled water    1 ltr 
 10% sterile solution of glucose 10ml 
 Sterile 20% urea solution 100ml 
Sterilize the glucose and urea solutions by filtration. Prepare the basal medium without 
glucose and urea, adjust to pH 6.8-6.9 and sterilize by autoclaving in a flask at 121°C for 
30min. Cool to about 50°C, add the glucose & urea, and tube the medium as slopes. 
 
5. Simmon's Citrate Medium 
Koser's medium   1 ltr 
Agar     20 g 
Bromothymol blue    0.2%   40ml  
Dispense, autoclave at 121°C for 15 min and allow to set as slopes 
 
6.Triple Sugar Iron medium 
Beef extract    3g 
Yeast extract    3g 
Peptone    20g 
Glucose    lg 
Lactose    10 g 
Sucrose    l0g 
Ferric citrate    0.3g 
Sodium chloride   5g 
S odum thiosulphate   0.3g 
Agar     12g 
Phenol red 0.2% solution  12ml 
Distilled water    1 ltr 
 
 Heat to dissolve the solids, add the indicator solution, mix and tube. Sterilize at 121°C 
for 15 min and cool to form slopes with deep butts. 
 
7. Glucose phosphate broth 
 Peptone    5g 
 Dipotassium hydrogen phosphate 5g 
 Water     1 ltr 
 Glucose 10% solution   50ml 
 
 Dissolve the peptone and phosphate and adjust the pH to 7.6. Filter dispense in 5ml 
amounts and sterilize at 121°C for 15min. Sterilize the glucose solution by filtration and add 
0.25ml to each tube. 
Methyl Red Reagent 
 Methyl Red    l0mg  
 Ethyl alcohol    30ml 
 Distilled water    20ml 
Voges Proskauer Reagent 
 Reagent A: Alpha naphthol  5g 
 Ethyl alcohol    100ml 
 Reagent B: Potassium hydroxide 40g 
 Distilled water    100ml 
 
8. Peptone water fermentation test medium. 
 To the basal medium of peptone water, add sterilised sugars of 1% indicator 
bromothymol blue with Durham's tube. Basal medium peptone water Sugar solutions: 
 Sugar      1ml 
 Dislilled water    100ml  
 pH = 7.6. 
9. Mannitol motility medium 
Agar     5g 
Peptone    lg 
Potassium nitrate   1g 
Mannitol     2g 
Phenol red indicator 
Distilled water    1000ml  
pH      7.2 
 
10.Phenolphthalein diphosphate agar 
 Sterilize a 1% aqueous solution of sodium phenolphthalein diphosphate by filtration 
and store at 4°C 
 Add 10ml of this solution to 1000ml melted nutrient agar cooled to 50°C and pour 
plates 
 Grow the staphylococcus overnight at 37°C on the medium 
 Invert the plate and pour a few drops of ammonia solution SG 0.88 into the lid 
 Read as positive a culture whose colonies turn bright pink within a few minutes. The 
colour soon fades 
 
11.2% Sodium deoxycholate solution: 
Ingredients : 
Sodium deoxycholate                                                          2 gms 
Distilled water                                                                     100ml 
Dissolve 2 gms of deoxycholate in 100 ml of distilled water .Mix 
well.Store in a sterile containers. 
 
12 .Decarboxylase media: 
8a.Moller decarboxylase broth base: 
Ingredients                                                                            gms/L 
Peptone                                                                                       5 
Beef extract                                                                                5 
Bromocresol purple                                                                0.01 
Cresol red                                                                               0.005 
Glucose                                                                                   0.5 
Pyridoxal                                                                                0.005 
Final pH 6 
 
8b. Aminoacid: 
Add 10 g of the levo form of the aminoacid for 1000ml.mix and dispense in sterile 
tubes. 
 
9.Hugh & Leifson’s Oxidation –Fermentation test: 
Peptone                                                                                     2g 
Sodium chloride                                                                       5g 
D-glucose                                                                                 10g 
Bromothymol blue                                                                   0.03g 
Agar                                                                                          3.0g 
Dipotassium phosphate                                                             0.30g 
Distilled water                                                                           1L 
pH =7.1 
 
 Basal medium is autoclaved.1% of sterile sugar solutions is added to the 
basal  medium.  Dispense into sterile test tubes without slant. 
 
10.Potassium nitrate broth 
Potassium nitrate (KNO3)  0.2gm 
Peptone    5.0gm 
Distilled water   100ml 
The above ingredients were mixed and transferred into tubes in 5 ml 
amount and autoclaved. 
 
11. Sugar fermentation medium 
Peptone                                                        15g 
Andrade's indicator   10 ml 
Sugar to be tested    20g 
Water     1 litre 
 
 Andrade's indicator is prepared from 0.5% aqueous acid fuchsin to which 
sufficient 1M sodium hydroxide has been added to turn the colour of the solution 
yellow. 
 
 Dissolve the peptone and Andrade's indicator in 1 litre of water and add 20g 
of the sugar; sugars to be tested generally include glucose, sucrose, lactose and 
maltose. Distribute 3ml amounts in standard test tubes containing an inverted 
Durham tube. Sterilize by steaming at 100 degree C for 30 min on 3 consecutive 
days. 
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ANNEXURE-II 
PROFORMA 
 
 Name :                                                                       IP no: 
 Age:                                                                           Ward:      
 Sex: 
 Occupation: 
 Address: 
Presenting complaints: 
• High grade fever- 
• Chills: 
• Sweating: 
• Dyspnea: 
• Tachypnea: 
• Chest pain: 
• Cough : 
• Sputum production: 
• Nature of sputum,volume 
• Hemoptysis: 
• headaches  
• loss of appetite: 
• excessive fatigue: 
• blueness of the skin (cyanosis): 
• diarrhea: 
• weight loss , Pedal edema  
• Altered sensorium  
• Musculoskeletal disorders(decrease lung func) 
• Upper respiratory infection 
• Gastroesophageal reflux 
•  aggravating and relieving factors 
Past history:  
previous episodes -asthma, bronchitis 
       TB ,  
        endocrine diseases,,  
        cardiac , 
        lung , 
        liver , 
        renal disorders , 
        chest injury,       
        hypertension, 
Personal history: 
• Alcohol intake: 
• Cigarette smoking: 
• Agriculture work: 
• Exposure to chemicals occupationally 
Family History 
Immunization History 
Drug  History 
Physical examination: 
Chest X ray findings: 
 lobar infiltrates or radiologic signs of pneumonia 
Pulmonary function test: 
 
Provisional diagnosis: 
Laboratory evaluation: 
Biochemical parameters: 
 Plasma glucose levels 
 Blood urea 
 Creatinine 
 Arterial blood gas analysis  
Hematological investigations: 
 TC 
 DC 
 Hb estimation 
 ESR 
Microbiological investigation: 
Sample collected: 
• Sputum:1)SPUTUM,2)INDUCED SPUTUM 
Bartlett score (for sputum sample): 
• BRONCHIAL WASH 
• ENDTRACHEAL ASPIRATE 
• Blood 
Direct examination: 
Gram’stain: 
AFB staining: 
KOH mount: 
 Bacterial Culture: 
 MAC 
 BAP 
 CAP 
  
Fungal culture: 
 SDA with antibiotics 
Blood culture: 
 Inoculated into Tryptic Soy broth with subculture onto 
o MAC 
o BAP 
o CAP 
Isolate identified in sample: 
 
Isolate identified in blood sample: 
 
Antibacterial susceptibility pattern: 
 
 
Antifungal susceptibility pattern: 
  
  
ANNEXURE-III 
CONSENT FORM 
 
STUDY TITLE: 
“Bacterial and fungal profile of acute exacerbation of Chronic obstructive 
pulmonary disease” 
 
I…………………………………………, hereby give consent to participate in 
the study conducted by Dr.V.R.Yamunadevi, Post graduate at Institute of 
Microbiology, Madras Medical College, Chennai and to use my personal 
clinical data and the result of investigations for the purpose of analysis and to 
study the nature of the disease, I also give consent to give my Sputum/BAL 
fluid/and Blood samples for further investigations. I also learn that there is no 
additional risk in this study. I also give my consent for my investigator to 
publish the data in any forum or journal  
  
   
 
Signature/ Thumb impression                                    Place:  
Of the patient/ relative                      Date: 
Patient Name & Address: 
 
 
Signature of the investigator: 
 
Signature of the guide: 
  
ANNEXURE-IV MASTER CHART-1 
 
 
 
 
   
MASTER CHART-2 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIBILIOGRAPHY 
 
BIBLIOGRAPHY 
 
1. Global Initiative for Obstructive Lung disease (GOLD) guidelines 2006 update 
2. Principles of Internal Medicine-18th edition Harrison.vol 2:2151-2160). 
3. Crofton, Douglas. “Chronic Bronchitis and Emphysema.” Chapter 23 in Crofton and 
Douglas’s Respiratory Disease – 1. 5th Edt. Antho-ny Seaton, Douglas Seaton, A. 
Gordon Leitfh eds. Blackwell science. C. 2000. P-616-695.  
4. Rodriguez-Roisin R Towards a consensus definition for COPD exacerbations 
.CHEST 2000 ;117 sppl 2:S398-401 
5. Lopez et.el.COPD current burden and future projections,EUR resp.Jour.2006 :27(2) 
:397-412 
6. Thiruvengadam KV, Sekar TS, Rajagopal KR. Study  of chronic  bronchitis in Tamil 
Nadu. Indian J Chest Dis 1974;16:1-10. 
7. Clinical presentation and predictors of outcome in patients with severe acute 
exacerbation of chronic obstructive pulmonary disease requiring admission to 
intensive care unit. 19 December 2006 BMC Pulmonary Medicine 2006, 6:27 
8. Bacterial infections in patients requiring admission for an acute  exacerbation of 
COPD; a 1-year prospective study Karin H. Groenewegen, Emiel F.M. Wouters 
Department of Pulmonology, University Hospital Maastricht, P.O. Box 5800, 
Maastricht 6202 AZ, The Netherlands Respiratory Medicine (2003) 97, 770–777 
9. Alfred Fishman:”Chronic obstructive pulmonary disease” Fishman’s Pulmonary 
diseases and disorders; 3rd edition ;vol 1:pg643-693 
10. S.K.Jindal ;Textbook of Pulmonary and critical medicine;1st  edition:971-1065 
11. Relationship Between Bacterial Flora in Sputum and Functional Impairment in 
Patients With Acute Exacerbations of COPD Chest. 1999;116(1):40-46) 
12. Thomas L Petty :The history of COPD :Int j of COPD 2006:3-14) 
13. Celli BR :A summary of ATS/ERS position paper. Eur. Resp jour 2004;23:932-946 
14. Global Initiative for COPD .Global strategy for diagnosis , management and 
prevention of COPD .http://www.goldcopd.com/Guidelineitem.asp(accessed April 
16, 2007). 
15. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES,Harding GK, Nelson NA. 
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. 
AnnIntern Med 1987; 106: 196±204. 
16. McCrory et al. Chest. 2001 Apr;119(4):1192 
17. WHO. WH statistics june 2010 www.who.int/resp/copd/burden/en/index.html 
18. Gerhson and collegues .Lifetime risk of developing COPD :A longitutidal population 
study Lancet 2011: 378:991-96 
19. Lopen AD and et al .Global and regional burden of disease and risk factor 
2001:systemic analysis of population health data :Lancet 2006:367:1747-57) 
20. Cohort study . Lancet 2007:370;751-57) 
21. Murray CJ ,Lopez AD. Mortality by cause for eight regions of the world :Global 
burden of disease study .Lancet 1997 ;349:1269-76 
22. Topley and Wilson’s Microbiology and Microbial infections ;10 th edition 
vol2:1864-1885 
23. David M.Mannino:Global burden of COPD :risk factors ,prevalence,and future trends   
24. Sethi & et.al.Infection in the pathogenesis and cause of COPD. N eng jour med 
2008;359;2355-65 
25. Sethi & et.al.Airway inflammation and bronchial bacterial colonization in COPD 
.AM J Respir crit care med;2006:173:991-98. 
26. Seemungal .et.al.Respiratory viruses ,symptoms ,inflammatory  markers  in 
AECOPD and stable COPD patients . AM J Respir crit care med;2001;164:1618-23 
27. Berenson & et.al.Impaired phagocytosis of nontypable H.influenza by human 
alveolar macrophages .Jour infectious diseases .2006;194:1375-84) 
28. Mandell, Douglas and Bennett’s Principles & Practise of Infectious diseases. 7th  
edition ;vol 1:877-884 
29. The role of atypical bacteria in exacerbations of COPD. European respiratory journal 
2007;30:240-44 
30. Microbial flora in normal lungs and bacteria in lower respiratory tract.AM .Rev 
respiratory Dis.1968;97:1051-1056. 
31. Donald et al. Interactions between lower airway bacterial at exacerbations of COPD 
Chest 2006;129:317-24 
32. Impaired phagocyosis by alveolar macrophages in COPD .J Inf disease 
2006;194:1375-84 
33. Thorax 2004;59(supp1):1-32),D.Behera .Textbook of Pulmonary Medicine ;2nd 
edition:vol 2(645-670) 
34. Bailey and scott’s. Diagnostic Microbiology.Twelfth edition, 
35. Mackie&McCartney .Practical Medical Microbiology.14th editon. 
36. Monica  Cheesbrough .District laboratory practice in tropical countries 2nd edition. 
part 2. 
37. Patrick r.murray ellen jo baren michael a. pfaller ; Manual of clinical 
microbiology;9th edition :vol1:318-320 
38. Koneman EW, Allen SD, Janda WM, Schreckenberger RC, Winn WC, editors. Color 
Atlas and text book of diagnostic microbiology. Lippincott-Raven; Philadephia: 
1997. pp. 121–171) 
39. I S Patel, T A R Seemungal, M Wilks,S J Lloyd-Owen, G C DonaldsonJ A Wedzicha 
et al. Relationship between bacterial colonisation and the frequency, character, and 
severity of COPD exacerbations; Thorax 2002;57:759-764 doi:10.1136/ 
thorax.57.9.759  
40. Traves S L, Culpitt S V, Russell R E. et al Increased levels of the chemokine 
GROalpha and MCP‐1 in sputum samples from patients with COPD. Thorax 2002. 
57590–595.595  
41. Hill A T, Bayley D, Stockley R A. The interrelationship of sputum inflammatory 
markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999. 
160893–898.898  
42. Yamamoto C, Yoneda T, Yoshikawa M. et al Airway inflammation in COPD 
assessed by sputum levels of interleukin‐8. Chest 1997. 112505–510.510  
43. Multidrug resistant pathogens Jane D,seagull et al. CDC. Management of Multidrug 
resistant organisms in Health care settings. Health care infection Advisory 
Committee 
44. AP Misra .Beta-Lactamase Threat in Respiratory Tract Infections: Focus on 
Cephalosporin-Clavulinic Acid ., New Delhi. Vol. 22ıMedicine Update 2012 75 
45. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for 
betalactamases and its correlation with molecular structure. Antimicrob Agents 
Chemother 1995; 39:1211-33 
46. Stephen P. Hawser  et al. Emergence of High Levels of Extended-Spectrum-β-
Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from 
the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007 
David L. Paterson Antimicrob. Agents Chemother. August 2009 vol. 53 no. 8 3280-
3284 
47. Laghawe. Avinash R, MS. Jaitly Neelam K. et al. Prevalence of AmpC 
Betalactamase in Gram- negative bacilli.Journal of Pharmaceutical and BioMedical 
Science / JPBMS, 2012, 2007 
48. S.singhal ,S khan ,DJ upadhyay et al.Evaluating methods for AmpC β lactamase in 
GN clinical isolates from TCH ;IJMM 2005 23 (2) 120-124 
49. Lee K,Lim YS ,Yong D,Yum jh,Chong y et al.Evaluation of the Hodge test and the 
Imipenem EDTA DDST for diff MBL producing of Psp & Asp ; JCM 2003 :4623-9 
50. Wattal C, Goel N, Oberoi JK et al. Surveillance of Multidrug ResistantOrganisms in 
a Tertiary Hospital in Delhi, India. JAPI 2010;58:32-36 82) Behera et al .An 
evaluation of four different phenotypic techniques 
51. Indian network for surveillance of anti microbial resistance INSAR in India. MRSA : 
prevalence and susceptibility pattern;IJMR 137 Feb 2013 :363-69 
52. Krishnan UMK,Shetty N.detection of methicillin and mupirocin resistance in 
Staphylococcus aureus isolates using conventional and molecular methods:a 
descriptive study from a burns unit with high prevalence of MRSA.j clin Pathology 
2002;55:745-8 
53. CDC Morbidity and Mortality weekly report ;Defining the Public Health Impact of 
Drug-Resistant Streptococcus pneumoniae February 16, 1996 / Vol. 45 / No. RR-1 
54. Prevalence of penicillin-resistant Streptococcus pneumoniae —Connecticut, 1992–
1993.MMWR 1994;43:216–7, 223 
55. Kurien Thomas. Epidemiology of Invasive Pneumococcal Disease in Adults in India. 
pg 598. Medicine Update 
56. Performance standards for antimicrobial susceptibility testing, CLSI 
document.M100-S-24.Vol 31.no 1.Table 2GJan 2014 
57. Dixon JMS, Miller DC. In: Stokes JE, Redgway GL, editors. Clinical 
Microbiology, 6th     ed. London: Edward Arnold Publ Ltd; 1987, pp 65 
58. G. M. TEBBUTT AND D. J. COLEMAN. Evaluation of some methods for the 
laboratory examination of sputum; Journal of Clinical Pathology, 1978, 31, 724-729 
59. Yoon Mi Shin1, Yeon-Mok Oh2, Mi Na Kim3, Tae Sun Shim2, Chae-Man Lim2, 
Sang Do Lee2, et al. Usefulness of Quantitative Endotracheal Aspirate Cultures in 
Intensive Care Unit Patients with Suspected Pneumonia ; J Korean Med Sci 2011; 
26: 865-869 
60. Performance standards for antimicrobial susceptibility testing; twenty-first 
informational supplement. clsi document m100-s21.vol. 31 no. 1. january 2014 
61. Suggested Groupings of Antimicrobial Agents With FDA Clinical Indications that 
should be Considered for Routine Testing and Reporting on Nonfastidious 
Organisms by Clinical Microbiology Laboratories. CLSI document M100-S21.Table 
1A. January 2014 
62. Zone Diameter and Minimal Inhibitory Concentration (MIC) Interpretive Standards 
for Enterobacteriaceae Pseudomonas,Acinetobacterand staphylococcus respectively. 
CLSI document M100-S21.Table 2A&2B &2C.January 2014 
63. Suggested Groupings of Antimicrobial Agents with FDA Clinical Indications that 
should be Considered for Routine Testing and Reporting on fastidious Organisms by 
Clinical Microbiology Laboratories. CLSI document M100-S21. Table 1B.January 
2014 
64. Zone Diameter and Minimal Inhibitory Concentration (MIC) Interpretive Standards 
for Streptococcus pneumonia & streptococcus viridians. CLSI document M100-
S21.Table 2G. January 2014 
65. Screening and confirmatory test for ESBL’s in Enterobacteriaceae isolates. CLSI 
document M100-S24.Table 3A-S1.Jan 2014.Vol 31.No.1 
66. Screening and confirmatory test for suspected carbapenamase production  in 
Enterobacteriaceae isolates. CLSI document M100-S24.Table 3C.Jan 2014.Vol 
31.No.1 
67. Screening Tests for β-Lactamase Production, Oxacillin Resistance, mecAMediated 
Oxacillin Resistance Using Cefoxitin,MIC ≥ 8 μg/mL, Inducible Clindamycin 
Resistance, and High-Level Mupirocin Resistance in the Staphylococcus aureus 
Group. CLSI document M100-S24. Table 3D,3E,3F S4. Jan 2014.Vol 31.No.1 
68. Performance standards for antimicrobial susceptibility testing, CLSI 
document.M100-S-24.Vol 31.no 1.Table 2GJan 2014. 
69. Jindal SK.A field study on the follow up at 10 years of prevalence of COPD and 
PEFR .IJMres 1993;98:20-26. 
70. Arora N., M.K. Daga et al. 2001 “Microbial pattern of Acute Infec-tive Exacerbation 
of Chronic Obstructive Airway Disease in a Hospi-tal Based Study”. Indian Chest 
Dis. Allied Sci.; 43: 157-162.  
71. Pallavi Torka, Surender K. Sharma; Microbial patterns in severe exacerbations of 
COPD; CHEST November 2010.  
72. Official Statement of the American Thoracic Society approved by the Board of 
Directors. “Standards for the diagnosis and Care of patients with Chronic Obstructive 
Pulmonary Disease.” A.M. J. Respir. Crit Care Med 1995; Vol.152 (March): p-S77-
S83. 
73. Sethi s.Bacterial infections and the pathogenesis of COPD .Chest 2000;117(5):286s-
91s. 
74. Stockley RA ,o’brien c,pye a,et al.Relationship to sputum color to nature and 
outpatient  Management of AECOPD.Chest 2000;117:1638-45 
75. Soler N,augusti  c,torres a .Bronchoscopic validation of the significance of sputum 
purulence in severe AECOPD . Thorax 2007;62:29-35 
76. Alladi mohan et al. Clinical presentation and predictors of outcome in patients with 
severe AECOPD requiring admissions to ICU ;BMC Pulmonary medicine:2006:6:27 
77. Chawla K, Mukhopadhay C, Majumdar M, Bairy , Bacteriological Profile and their 
Antibiogram from Cases of Acute Exacerbations of Chronic Obstructive Pulmonary 
Disease: A Hospital Based Study  Journal of Clinical and Diagnostic Research 2008 , 
2,612-616. 
78. Alamoudi OS et al.Bacterial infections and risk factors in op with AECOPD :2 year 
propective study;Respirology 2007 Mar;12(2):283-7 
79. Laura solano et al.Chronic Pseudomonas aeruginosa Infection in Chronic Obstructive 
Pulmonary Disease;oxford journal of clinical infectious diseases.2008 (47):1526-
1533 
80. Eller jorg et al.Infective exacerbation of chronic bronchitis.Chest 1998;113:1542-
1548) 
81. N.roche et al.Yield of sputum microbiological examination in patients hosp for 
AECOPD with purulent sputum;Resp J 2007;74:19-25 
82. Niederman micheal s et al.antibiotic therapy of chronic bronchitis.jour in resp 
infection 2000;vol 15 mar:15-60) 
83. Karin H. Groenewegen, Emiel F.M. Wouters et al .for an acute exacerbation of 
COPD; a 1-year prospective study; Respiratory Medicine (2003) 97, 770–777 
84. Pradhan K.C., Sudharani Kar, B.K. Nanda. 1979 “Bacteriology of Chronic 
Respiratory Disease of Non-Tubercular Origin.” Indian J. Pathol Microbiol; Vol.22 
(April) : 133-138. 
85. Cinthujah B et al.Bacteriological Profile and Antibiogram of Chronic Obstructive 
Pulmonary Disease Cases- A Prospective Study  Tirunelveli e Journal of Medical 
Sciences tejms:2012 
86. Madhavi S et al Bacterial etiology of acute exacerbations of chronic obstructive 
pulmonary disease J. Microbiol. Biotech. Res., 2012, 2 (3):440-444) . 
87. Wilson Robert. 1998 “The Role of Infection in COPD.” Chest Vol.133:242 S-248 S.) 
88. McHardy V U, Inglis J M, Calder M A. et al A study of infective and other factors in 
exacerbations of chronic bronchitis. Chest 1980. 74228–238.238.  
89. Zalacain R, Sobradillo V, Amilibia J. et al Predisposing factors to bacterial 
colonisation in chronic obstructive pulmonary disease. Eur Respir J 1999. 13343–
348.348) 
90. Monso et al.Bacterialinfection in COPD :a study of stable and exacerbated using 
protected brush specimen.AM J Resp cri care med 1995;152:1316-20 
91. Rosell et al.Microbiological determinants of AECOPD.Arch Intern med 
2005;165:891-89)   
92. A marin et al.Variability and effects of bronchial colonisation in patients with 
moderate COPD; European Respiratory Journal 2010;Volume 35 Number 2:295-
302) 
93. Gerard Rakesh1, T.Kasturi2 and S.Yuvarajan3 Int.J.Curr.Microbiol.App.Sci (2013) 
2(11): 273-282 Bacterial agents causing acute exacerbations in Chronic Obstructive 
Pulmonary Disease (COPD) patients, their antibiograms to Extended Spectrum Beta-
Lactamases (ESBL) production in a tertiary care hospital, India  
94. Fanny w s et al.A one  year prospective study of the infectious etiology in patients 
hospitalised with AECOPD;Chest 2007;131(1) 44-52 
95.  Fluit, A. C., Verhoef, J., Schmitz, F.-J. & the European SENTRY participants. 
(2000). Antimicrobial resistance in European isolates of Pseudomonas aeruginosa. 
European Journal of Clinical Microbiology and Infectious Diseases 19, 370–4 
96. Jones, R. N., Beach, M. L. & Pfaller, M. A. (2001). Spectrum and activity of three 
contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from 
urinary tract infections in the SENTRY antimicrobial surveillance program (Europe 
and the Americas; 2000): more alike than different! Diagnostic Microbiology and 
Infectious Disease 41, 161–3. 
97. Centers for Disease Control and Prevention. Acinetobacter baumannii infections 
among patients at military medical facilities treating injured U.S. service members, 
2002–2004. MMWR Morb Mortal Wkly Rep 2004;53:1063-6. 
98. Lisa L et al .Acinetobacter baumannii: Epidemiology, Antimicrobial Resistance, and 
Treatment ;Oxford journal in clinical infectious disease Volume 46, Issue 8 Pp. 
1254-1263 
99. Indian network for surveillance of anti microbial resistance INSAR in India.MRSA  
:prevalence and susceptibility pattern;IJMR 137 Feb 2013 :363-69). 
100. CDC. Prevalence of penicillin-resistant Streptococcus pneumoniae —Connecticut, 
1992–1993.MMWR 1994;43:216–7, 223. 
101. Goyal et al.   Antimicrobial resistance in invasive and colonising Streptococcus 
pneumoniae in North India; IJMM 2007  ;Volume : 25 : 256-259 
102. Iain B Gosbell,1,2 Stephen A Neville1 .Antimicrobial resistance in Streptococcus 
pneumoniae: a decade of results from south-western Sydney. Commun Dis Intell 
2000;24:340-343. 
103. Emilio Perez –trallero et al .Antimicrobial Susceptibilities and Serotypes of 
Streptococcus pneumoniae Isolates from Elderly Patients with Pneumonia and Acute 
Exacerbation of Chronic Obstructive Pulmonary Disease .Antimicrob Agents 
Chemother. Jun 2011; 55(6): 2729–2734. ) 
104. Stephen P. Hawser  et al. Emergence of High Levels of Extended-Spectrum-β-
Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from 
the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007 
David L. Paterson Antimicrob. Agents Chemother. August 2009 vol. 53 no. 8 3280-
3284) 
105. Detection methods for drug resistant Streptococcus pneumoniae Performance 
standards for antimicrobial susceptibility testing, CLSI document.M100-S-24.Vol 
31.no 1.Table 2GJan 2014. 
106. CLSI guidelines M100-S24 Table 8A; 186-187:January 2014 
107. Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. 
Clin Microbiol Infect 2008; 14 (suppl 1): 159-165. 
108. Henry’s Clinical diagnosis and management by laboratory methods;21st edition DA 
Mc person 
109. Manson’s tropical disease ;Jeremy farrar,Peter:23rd edition 
110. Infectious disease :Jonathan cohen :3rd  edition ;vol 1 
111. Manual of Clinical microbiology ;James wersalovick:10th edition. 
112. Allegra, L., N. Konietzko, P, Leophonte, et al. 1996. Comparative safety and efficacy 
of sparfloxacin in the treatment of acute exacerbations of chronic obstructive 
pulmonary disease: a double-blind, randomised, parallel,multicentre study. J 
Antimicrob Chemother. 37(Suppl A):93 104.American Lung Association. 2011. 
113. Rennard SI, Farmer SG. Exacerbations and progression of disease  in asthma and 
chronic obstructive pulmonary disease. Proc Am Thorac soc2004;1:88-92. 
114. Bacterial etiology of acute exacerbations of chronic obstructive pulmonary Disease 
Scholars Research Library J. Microbiol. Biotech. Res., 2012, 2 (3):440-444 
 
